<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="/resources/spdi-openaccess-jats.xsl"?>
<!DOCTYPE response [
	
<!ENTITY % article SYSTEM "http://jats.nlm.nih.gov/archiving/1.2/JATS-archivearticle1.dtd">
<!ENTITY % book-part-wrapper SYSTEM "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
	]><response><apiMessage>This XML was provided by Springer Nature</apiMessage><query>doi:10.1038/s41430-018-0377-6</query><apiKey>6b19ee21fe6a243741a528650f7c8997</apiKey><result><total>1</total><start>1</start><pageLength>1</pageLength><recordsDisplayed>1</recordsDisplayed></result><records><article dtd-version="1.2" article-type="review-article" xml:lang="en" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink"><?properties open_access?><front><journal-meta><journal-id journal-id-type="publisher-id">41430</journal-id><journal-id journal-id-type="doi">10.1038/41430.1476-5640</journal-id><journal-title-group><journal-title>European Journal of Clinical Nutrition</journal-title><abbrev-journal-title abbrev-type="publisher">Eur J Clin Nutr</abbrev-journal-title></journal-title-group><issn pub-type="ppub">0954-3007</issn><issn pub-type="epub">1476-5640</issn><publisher><publisher-name>Nature Publishing Group UK</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">s41430-018-0377-6</article-id><article-id pub-id-type="manuscript">377</article-id><article-id pub-id-type="doi">10.1038/s41430-018-0377-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group><subj-group subj-group-type="SubjectPath"><subject>/692/499</subject></subj-group><subj-group subj-group-type="SubjectPath"><subject>/692/699/255</subject></subj-group><subj-group subj-group-type="NatureArticleTypeID"><subject>review-article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Effects of prebiotics on sepsis, necrotizing enterocolitis, mortality, feeding intolerance, time to full enteral feeding, length of hospital stay, and stool frequency in preterm infants: a meta-analysis</article-title></title-group><contrib-group><contrib contrib-type="author" id="Au1"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-4908-0307</contrib-id><name><surname>Chi</surname><given-names>Cheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" id="Au2"><name><surname>Buys</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" id="Au3"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7810-9506</contrib-id><name><surname>Li</surname><given-names>Cheng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au4"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0097-2438</contrib-id><name><surname>Sun</surname><given-names>Jing</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="corresp" rid="IDs4143001803776_cor4">d</xref></contrib><contrib contrib-type="author" corresp="yes" id="Au5"><name><surname>Yin</surname><given-names>Chenghong</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="corresp" rid="IDs4143001803776_cor5">e</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0369 153X</institution-id><institution-id institution-id-type="GRID">grid.24696.3f</institution-id><institution content-type="org-division">Department of Internal Medicine, Beijing Obstetrics and Gynecology Hospital</institution><institution content-type="org-name">Capital Medical University</institution></institution-wrap><addr-line content-type="city">Beijing</addr-line><country country="CN">China</country></aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0437 5432</institution-id><institution-id institution-id-type="GRID">grid.1022.1</institution-id><institution content-type="org-division">Menzies Health Institute Queensland</institution><institution content-type="org-name">Griffith University</institution></institution-wrap><addr-line content-type="city">Gold Coast</addr-line><addr-line content-type="state">QLD</addr-line><country country="AU">Australia</country></aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0437 5432</institution-id><institution-id institution-id-type="GRID">grid.1022.1</institution-id><institution content-type="org-division">School of Medicine</institution><institution content-type="org-name">Griffith University</institution></institution-wrap><addr-line content-type="city">Gold Coast</addr-line><country country="AU">Australia</country></aff></contrib-group><author-notes><corresp id="IDs4143001803776_cor4"><label>d</label><email>j.sun@griffith.edu.au</email></corresp><corresp id="IDs4143001803776_cor5"><label>e</label><email>modscn@126.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>19</day><month>12</month><year>2018</year></pub-date><pub-date date-type="pub" publication-format="print"><month>5</month><year>2019</year></pub-date><volume>73</volume><issue seq="3">5</issue><fpage>657</fpage><lpage>670</lpage><history><date date-type="registration"><day>30</day><month>11</month><year>2018</year></date><date date-type="received"><day>1</day><month>7</month><year>2018</year></date><date date-type="rev-recd"><day>25</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>26</day><month>11</month><year>2018</year></date><date date-type="online"><day>19</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>© The Author(s) 2018</copyright-statement><copyright-year>2018</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link xlink:href="http://creativecommons.org/licenses/by/4.0/" ext-link-type="url">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1" xml:lang="en"><title>Abstract</title><sec id="ASec1"><title>Background/Objectives</title><p id="Par1">Prebiotics are increasingly recognized as an effective measure to promote health and prevent adverse health outcomes in preterm infants. We aimed to systematically review the randomized controlled trials (RCTs) in this area.</p></sec><sec id="ASec2"><title>Subjects/Methods</title><p id="Par2">Relevant studies from January 2000 to June 2018 were searched and selected from PubMed, Medline, Scopus, and the Cochrane Library. RCTs were included if they involved preterm infant participants, included a prebiotic intervention group, measured incidence of sepsis, feeding intolerance, mortality, time to full enteral feeding, necrotizing enterocolitis (NEC), length of hospital stay, and stool frequency as outcomes.</p></sec><sec id="ASec3"><title>Results</title><p id="Par3">Eighteen RCTs (<italic>n</italic> = 1322) were included in the final meta-analysis. Participants who took prebiotics showed significant decreases in the incidence of sepsis (with a risk ratio (RR) of 0.64, 95% CI: 0.51, 0.78), mortality (RR = 0.58. 95% CI: 0.36, 0.94), length of hospital stay (mean difference (MD): −5.18, 95% CI: −8.94, −1.11), and time to full enteral feeding (MD: −0.99, 95% CI: −1.15, 0.83). The pooled effects showed no significant differences between intervention and control groups in relation to the morbidity rate of NEC (RR = 0.79, 95% CI: 0.44, 1.44) or feeding intolerance (RR = 0.87, 95% CI: 0.52, 1.45).</p></sec><sec id="ASec4"><title>Conclusions</title><p id="Par4">The results showed that the use of prebiotics with preterm infants is safe and can decrease the incidence of sepsis, mortality, length of hospital stay, and time to full enteral feeding but not NEC.</p></sec></abstract><custom-meta-group><custom-meta><meta-name>publisher-imprint-name</meta-name><meta-value>Springer Nature</meta-value></custom-meta><custom-meta><meta-name>volume-issue-count</meta-name><meta-value>12</meta-value></custom-meta><custom-meta><meta-name>issue-article-count</meta-name><meta-value>21</meta-value></custom-meta><custom-meta><meta-name>issue-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>issue-pricelist-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-holder</meta-name><meta-value>Springer Nature Limited</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>article-contains-esm</meta-name><meta-value>Yes</meta-value></custom-meta><custom-meta><meta-name>article-numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-year</meta-name><meta-value>2018</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-month</meta-name><meta-value>11</meta-value></custom-meta><custom-meta><meta-name>article-registration-date-day</meta-name><meta-value>30</meta-value></custom-meta><custom-meta><meta-name>article-toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>toc-levels</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>volume-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>journal-product</meta-name><meta-value>NonStandardArchiveJournal</meta-value></custom-meta><custom-meta><meta-name>numbering-style</meta-name><meta-value>Unnumbered</meta-value></custom-meta><custom-meta><meta-name>article-grants-type</meta-name><meta-value>OpenChoice</meta-value></custom-meta><custom-meta><meta-name>metadata-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>abstract-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodypdf-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bodyhtml-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>bibliography-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>esm-grant</meta-name><meta-value>OpenAccess</meta-value></custom-meta><custom-meta><meta-name>online-first</meta-name><meta-value>false</meta-value></custom-meta><custom-meta><meta-name>pdf-file-reference</meta-name><meta-value>BodyRef/PDF/41430_2018_Article_377.pdf</meta-value></custom-meta><custom-meta><meta-name>target-type</meta-name><meta-value>OnlinePDF</meta-value></custom-meta><custom-meta><meta-name>issue-online-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-online-date-month</meta-name><meta-value>5</meta-value></custom-meta><custom-meta><meta-name>issue-online-date-day</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-print-date-year</meta-name><meta-value>2019</meta-value></custom-meta><custom-meta><meta-name>issue-print-date-month</meta-name><meta-value>5</meta-value></custom-meta><custom-meta><meta-name>issue-print-date-day</meta-name><meta-value>1</meta-value></custom-meta><custom-meta><meta-name>issue-type</meta-name><meta-value>Regular</meta-value></custom-meta><custom-meta><meta-name>article-type</meta-name><meta-value>ReviewPaper</meta-value></custom-meta><custom-meta><meta-name>journal-subject-primary</meta-name><meta-value>Medicine &amp; Public Health</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Medicine/Public Health, general</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Public Health</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Epidemiology</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Internal Medicine</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Clinical Nutrition</meta-value></custom-meta><custom-meta><meta-name>journal-subject-secondary</meta-name><meta-value>Metabolic Diseases</meta-value></custom-meta><custom-meta><meta-name>journal-subject-collection</meta-name><meta-value>Medicine</meta-value></custom-meta><custom-meta><meta-name>open-access</meta-name><meta-value>true</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Introduction</title><p id="Par5">Due to advances in medical technology, outcomes for preterm infants treated in neonatal intensive care units (NICUs) have improved during the latest 20 years [<xref ref-type="bibr" rid="CR1">1</xref>]. However, more than 40% of very preterm infants still die before discharge or suffer from one or more serious complications [<xref ref-type="bibr" rid="CR2">2</xref>] that can lead to further poor neurodevelopmental outcomes [<xref ref-type="bibr" rid="CR3">3</xref>]. Most preterm infant deaths, especially those born&lt;28 weeks gestation, were caused by infections, including sepsis and necrotizing enterocolitis (NEC). These morbidities are associated with increased mortality, morbidity, and prolonged lengths of hospital stay [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>].</p><p id="Par6">The gut microbial composition of preterm infants is quite different from that of full-term infants. Preterm infants have low bacterial diversity and a different gut microbiota, with more Proteobacteria and <italic>Enterococcus</italic>, which are regarded as potential pathogenic bacteria in their intestinal tract [<xref ref-type="bibr" rid="CR5">5</xref>]. In addition, the digestive system of preterm infants is immature, with an underdeveloped intestinal mucosa barrier [<xref ref-type="bibr" rid="CR6">6</xref>]. Pathogens and bacterial toxins can pass through their gut barrier easily and enter blood and lymph circulation, leading to life-threatening infections, including sepsis, NEC, and diarrhea. There are many factors that may lead to intestinal dysbacteriosis of preterm infants, such as lack of fresh breast milk, delayed introduction of enteral feeding, and excessive antibiotic use in the NICU [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. After birth, most preterm infants stay in the hospital to receive observation and treatment for at least 1–2 weeks, which can expose them to a higher incidence of opportunistic infections [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par7">In recent years, much attention has been given to providing preterm infants with prebiotics supplements to promote growth and development and prevention of various morbidities. Prebiotics supplementation in preterm infants may facilitate the growth and proliferation of probiotic bacteria in their intestinal tract and has been found to prevent the overgrowth of pathogens and promote the maturation of the intestinal mucosa. However, due to their immature immune and digestive systems [<xref ref-type="bibr" rid="CR9">9</xref>], prebiotic supplementation dosage levels should be considered carefully to avoid feeding intolerance.</p><p id="Par8">Non-human milk oligosaccharides, which have been manufactured to function in a similar manner to oligosaccharides in breast milk [<xref ref-type="bibr" rid="CR7">7</xref>], include neutral short-chain galacto-oligosaccharides (scGOS), long-chain fructo-oligosaccharides (lcFOS), and pectin-derived acidic oligosaccharides (pAOS). In addition to neutral oligosaccharides (scGOS/lcFOS), few clinical trials are concerned with acidic oligosaccharides (pAOS), which could directly modify the immune system of infants [<xref ref-type="bibr" rid="CR7">7</xref>].</p><p id="Par9">Many meta-analyses focused on evaluating if probiotics have shown beneficial effects in preterm infants, but few have focused on the effect of prebiotics. Furthermore, there are no meta-analyses that evaluate the effect of pAOS in relation to preterm infants. We aimed to perform a meta-analysis of studies published over the past 18 years, in which randomized control trials (RCTs) were used to evaluate whether prebiotics could confer a health benefit to preterm infants, especially in reducing the incidence of sepsis, NEC, and mortality. Furthermore, this study also considered other important outcomes in preterm infants, including prolonged length of hospital stay, feeding intolerance, and stool frequency.</p></sec><sec id="Sec2" sec-type="methods"><title>Methods</title><sec id="Sec3"><title>Search strategy</title><p id="Par10">The study protocol was registered in the PROSPERO database (registration ID: CRD42017068320). The PICO approach was used to assist in identifying relevant studies as follows: P (population): study population comprising preterm or low birth weight infants, and all trials involved human participants; I (intervention): use one of the following supplements as intervention: scGOS, lcFOS, pAOS, oligosaccharides, fructans, inulin, or oligofructose as intervention; C (comparison): placebo-controlled trials involved participants randomized allocation to treatment groups; O (outcome): report one or more of the following outcomes: morbidity rate of sepsis, NEC, mortality, feeding intolerance, time to achieve full enteral feeding, stool frequency, and length of hospital stay. If the authors published multiple articles from the same population, we only chose those with the largest sample sizes and the longest intervention duration.</p><p id="Par11">The following items were combined and used to conduct a systematic search to identify suitable trials: prebiotics AND preterm infant or low weight birth infant AND search filters for RCTs. When relevant data was not adequately provided in articles, we contacted the authors by e-mail in an attempt to retrieve the missing information needed for the meta-analysis.</p></sec><sec id="Sec4"><title>Inclusion criteria</title><p id="Par12">We used the following criteria to determine the inclusion of RCTs: (1) Published in a peer-reviewed journal in the past 18 years (January 2000 until June 2018); (2) Study design was a RCT; (3) Participants included low birth weight infants (&lt;2500 g) or preterm infants (&lt;36 weeks); (4) Prebiotics and placebo were supplied to different groups as an intervention; and (5) Outcome variables included incidence of sepsis, NEC, mortality, time to achieve full enteral feeding, feeding intolerance, stool frequency, and length of hospital stay.</p></sec><sec id="Sec5"><title>Data extraction and quality assessment</title><p id="Par13">Two researchers independently extracted data and conducted an assessment of trials according to the criteria above. Relevant studies from January 2000 to June 2018 were searched and selected from PubMed, Medline, Scopus, and the Cochrane Library. A summary of the review was presented using the PRISMA flow chart (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). We extracted the following data from each of the included articles: study location, population, study design, type of prebiotics, and placebo used as the intervention, details of the main study endpoints, blinding, form and dosage of prebiotics used, duration, information to assess the risk of bias, and major outcomes reported. We used the Physiotherapy Evidence Database (PEDro) tool to evaluate the quality of the included literature. Studies were then categorized into three levels using the tool (high, 8 or more points; moderate, 4–7 points; low, 3 points or less). Studies that were categorized as moderate or high quality were included in the analysis, while poor studies were excluded.<fig id="Fig1"><label>Fig. 1</label><caption xml:lang="en"><p>The preferred reporting items for systematic reviews and meta-analyses flow chart representing the reviewing process</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41430_2018_377_Fig1_HTML.png"/></p></fig></p></sec><sec id="Sec6"><title>Statistical analysis</title><p id="Par14">A pooled effect size method was used to describe the effect of prebiotics on health outcome variables. We used random effect models to assess the between-study variation. Risk ratios were calculated to examine the effect size for sepsis, NEC, mortality, and feeding intolerance. Mean difference was used to present the effect of time to achieve full enteral feeding, stool frequency as well as length of hospital stay. The pooled mean difference with a 95% Confidence Interval (CI) was figured up to assess the effects of prebiotics on the infants’ health outcomes. Several methods were used to estimate heterogeneity among the pooled studies, including <italic>I</italic><sup>2</sup> statistics as well as visual inspection of CI overlap. Low heterogeneity was defined as trials with <italic>I</italic><sup>2</sup> &lt; 50%. We performed a subgroup analysis to identify the sources of heterogeneity associated with the effects of birth weight (&lt;1500 g compared with 1500–2500 g), duration of intervention (&lt;28 days compared with 28 days or more), quality of RCTs (high compared with moderate), the forms of prebiotics used (milk compared with other forms), dosage of prebiotics (&lt;1.5 g/kg/day vs. 1.5 g/kg/day), and type of prebiotics (pAOS compared with no pAOS). The Egger test was used to assess any publication bias together with a visual inspection of funnel plots. Sensitivity analyses were performed to assess whether the efficacy of prebiotics was derived from one particular trial or multiple trials.</p></sec></sec><sec id="Sec7" sec-type="results"><title>Results</title><p id="Par15">In the initial systematic search, 105 articles were identified from the databases listed above (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). After duplications were removed, 47 articles were listed. After reading titles and abstracts, 30 potentially relevant articles were identified. Full articles were retrieved and reviewed, then another 12 studies were excluded (six due to insufficient data, four due to not focusing on preterm infants, two due to being non-human population RCT’s). The final statistical analysis was conducted with the remaining 18 articles, which consisted of 12 high quality (8 points or more) and six moderate quality (4–7 points) articles.</p><p id="Par16">The 18 RCTs reported health outcomes on 647 infants given prebiotics and 675 infants as control. Samples were drawn from ten different locations, including Iran [<xref ref-type="bibr" rid="CR10">10</xref>–<xref ref-type="bibr" rid="CR12">12</xref>], Netherlands [<xref ref-type="bibr" rid="CR13">13</xref>–<xref ref-type="bibr" rid="CR18">18</xref>], Turkey [<xref ref-type="bibr" rid="CR19">19</xref>], Greece [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>], Finland [<xref ref-type="bibr" rid="CR22">22</xref>], France [<xref ref-type="bibr" rid="CR23">23</xref>], Israel [<xref ref-type="bibr" rid="CR24">24</xref>], England [<xref ref-type="bibr" rid="CR25">25</xref>], Germany [<xref ref-type="bibr" rid="CR26">26</xref>], and Italy [<xref ref-type="bibr" rid="CR27">27</xref>]. Among the 18 trials, 11 were double-blinded [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR26">26</xref>], and the rest seven were single blinded [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR16">16</xref>–<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. All studies included one or more of the following outcomes: incidence of sepsis, NEC, death, time to full achieve enteral feeding, feeding intolerance, stool frequency, and length of time in hospital. The characteristics of included trials and quality assessment results are presented in Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1"><label>Table 1</label><caption xml:lang="en"><p>Characteristics of 18 included randomized controlled trials</p></caption><table frame="hsides" rules="groups"><thead><tr><th><p>Studies</p></th><th><p>Participants at beginning, <italic>n</italic> (P/C)</p></th><th><p>Design, location</p></th><th><p>Gestational age, P/C, week</p></th><th><p>Birth weight, P/C, g</p></th><th><p>Sex, <italic>n</italic> (P/C, M/F)</p></th><th><p>Treatment duration, days</p></th><th><p>Prebiotics used</p></th><th><p>Dose</p></th><th><p>Placebo</p></th><th><p>Measured outcomes</p></th><th><p>Key outcomes</p></th><th><p>Quality of studies assessed by PEDro tool</p></th><th><p>Form</p></th></tr></thead><tbody><tr><td><p>Armanian et al. [<xref ref-type="bibr" rid="CR11">11</xref>]</p></td><td><p>50 (25/25)</p></td><td><p>DB, Iran</p></td><td><p>30.48 (2.31)/29.80 (2.16)</p></td><td><p>1.262 (0.213)/1.188 (0.194)</p></td><td><p>Not mentioned</p></td><td><p>21</p></td><td><p>scGOS/lcFOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Distilled water</p></td><td><p>Fecal microbiota pattern, duration of dependency to oxygen, hospitalization, and death</p></td><td><p>Led to the rapid growth of beneficial Lactobacillus colonies</p></td><td><p>11</p></td><td><p>Mixture solution</p></td></tr><tr><td><p>Van den Berg et al. [<xref ref-type="bibr" rid="CR18">18</xref>]</p></td><td><p>77 (38/39)</p></td><td><p>SB, Netherlands</p></td><td><p>29.9 (1.7)/29.6 (2.1)</p></td><td><p>1.32 (0.38)/1.28 (0.28)</p></td><td><p>21/17, 24/15</p></td><td><p>28</p></td><td><p>scGOS/lcFOS/pAOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Breast milk or formula</p></td><td><p>Neurodevelopment, cytokines, and infections</p></td><td><p>No significant improvement of neurodevelopmental outcomes</p></td><td><p>8</p></td><td><p>With breast milk or formula</p></td></tr><tr><td><p>Armanian et al. [<xref ref-type="bibr" rid="CR12">12</xref>]</p></td><td><p>50 (25/25)</p></td><td><p>DB, Iran</p></td><td><p>30.4 (2.3)/29.8 (2.1)</p></td><td><p>1.262 (0.213)/1.188 (0.194)</p></td><td><p>Not mentioned</p></td><td><p>7</p></td><td><p>scGOS/lcFOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Distilled water</p></td><td><p>Bilirubin level and stool frequency</p></td><td><p>Increase stool frequency, improve feeding tolerance, and reduce bilirubin level</p></td><td><p>11</p></td><td><p>Mixture solution</p></td></tr><tr><td><p>Dilli et al. [<xref ref-type="bibr" rid="CR19">19</xref>]</p></td><td><p>200 (50/50)</p></td><td><p>DB, Turkey</p></td><td><p>29.0 (1.7)/28.2 (2.2)</p></td><td><p>1.229 (0.246)/1.147 (0.271)</p></td><td><p>52/48, 58/42</p></td><td><p>56</p></td><td><p>Inulin</p></td><td><p>1.35 g/kg/day</p></td><td><p>Maltodextrin</p></td><td><p>NEC, sepsis, mortality, duration of hospital</p></td><td><p>Inulin could not decrease NEC</p></td><td><p>10</p></td><td><p>With breast milk or formula</p></td></tr><tr><td><p>Armanian et al. [<xref ref-type="bibr" rid="CR10">10</xref>]</p></td><td><p>75 (25/50)</p></td><td><p>SB, Iran</p></td><td><p>30.48 (2.31)/30.38 (2.53)</p></td><td><p>1.263 (0.213)/1.206 (0.177)</p></td><td><p>Not mentioned</p></td><td><p>14</p></td><td><p>scGOS/lcFOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Distilled water</p></td><td><p>NEC, mortality, sepsis, feeding intolerance, and days to reach full enteral feeding</p></td><td><p>Lower NEC, mortality, sepsis rates, and shorter days to reach full enteral feeding</p></td><td><p>8</p></td><td><p>With breast milk or formula</p></td></tr><tr><td><p>Dasopoulou et al. [<xref ref-type="bibr" rid="CR21">21</xref>]</p></td><td><p>167 (85/82)</p></td><td><p>DB, Greece</p></td><td><p>34.0 (0.33)/34.0 (0.33)</p></td><td><p>2.019 (0.30)/1.987 (0.38)</p></td><td><p>Not mentioned</p></td><td><p>16</p></td><td><p>scGOS/lcFOS</p></td><td><p>1.2 g/kg/day</p></td><td><p>Formula</p></td><td><p>Motilin, NEC, mortality, sepsis, and feeding intolerance</p></td><td><p>Increase motilin, reduce gastric residue</p></td><td><p>11</p></td><td><p>With formula</p></td></tr><tr><td><p>Luoto et al. [<xref ref-type="bibr" rid="CR22">22</xref>]</p></td><td><p>47 (23/24)</p></td><td><p>DB, Finland</p></td><td><p>32–35</p></td><td><p>2.123 (0.39)/2.412 (0.84)</p></td><td><p>11/12, 19/5</p></td><td><p>57</p></td><td><p>scGOS/polydextrose</p></td><td><p>1.2 g/kg/day</p></td><td><p>Microcrystalline cellulose and dextrose anhydrate</p></td><td><p>Respiratory tract infections and its duration</p></td><td><p>Reduce the risk of rhinovirus infections</p></td><td><p>11</p></td><td><p>With breast milk or formula</p></td></tr><tr><td><p>Van den Berg et al. [<xref ref-type="bibr" rid="CR16">16</xref>]</p></td><td><p>103 (55/58)</p></td><td><p>SB, Netherlands</p></td><td><p>29.9 (1.9)/29.3 (2.1)</p></td><td><p>1.3 (0.4)/1.2 (0.3)</p></td><td><p>31/24, 36/22</p></td><td><p>28</p></td><td><p>scGOS/lcFOS/pAOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Maltodextrin</p></td><td><p>Serious infectious morbidity</p></td><td><p>Does not improve the immunization response</p></td><td><p>10</p></td><td><p>With breast milk or formula</p></td></tr><tr><td><p>LeCouffe et al. [<xref ref-type="bibr" rid="CR17">17</xref>]</p></td><td><p>113 (48/45)</p></td><td><p>SB, Netherlands</p></td><td><p>30.2 (1.6)/29.5 (2.0)</p></td><td><p>1.37 (0.4)/1.26 (0.3)</p></td><td><p>26/48, 26/45</p></td><td><p>28</p></td><td><p>scGOS/lcFOS/pAOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Maltodextrin</p></td><td><p>Neurodevelopmental outcome</p></td><td><p>No effect on neurodevelopmental</p></td><td><p>8</p></td><td><p>With breast milk or formula</p></td></tr><tr><td><p>Niele et al. [<xref ref-type="bibr" rid="CR15">15</xref>]</p></td><td><p>114 (48/46)</p></td><td><p>DB, Netherlands</p></td><td><p>30.1 (1.6)/29.5 (2.0)</p></td><td><p>1.40 (0.4)/1.30 (0.3)</p></td><td><p>Not mentioned</p></td><td><p>28</p></td><td><p>scGOS/lcFOS/pAOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Maltodextrin</p></td><td><p>Allergic and infectious diseases</p></td><td><p>Does not decrease the incidence of allergic and infectious diseases</p></td><td><p>10</p></td><td><p>With breast milk or formula</p></td></tr><tr><td><p>Westerbeek et al. [<xref ref-type="bibr" rid="CR14">14</xref>]</p></td><td><p>103 (55/58)</p></td><td><p>DB, Netherlands</p></td><td><p>29.9 (1.9)/29.3 (2.1)</p></td><td><p>1.3 (0.4)/1.2 (0.3)</p></td><td><p>31/24, 36/22</p></td><td><p>28</p></td><td><p>scGOS/lcFOS/pAOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Maltodextrin</p></td><td><p>Stool viscosity, stool frequency, and stool pH</p></td><td><p>Decreases stool viscosity and stool pH, increased stool frequency</p></td><td><p>11</p></td><td><p>With breast milk or formula</p></td></tr><tr><td><p>Campeotto et al. [<xref ref-type="bibr" rid="CR23">23</xref>]</p></td><td><p>58 (24/34)</p></td><td><p>DB, France</p></td><td><p>33.5 (1.3)/33.4 (1.1)</p></td><td><p>1.91 (0.35)/1.93 (0.39)</p></td><td><p>15/9, 16/18</p></td><td><p>30</p></td><td><p>Fermente induced non-digestible oligosaccharides</p></td><td><p>Not mentioned</p></td><td><p>Formula</p></td><td><p>Inflammatory and immune markers</p></td><td><p>Benefits on inflammatory and immune markers</p></td><td><p>10</p></td><td><p>Formula</p></td></tr><tr><td><p>Riskin et al. [<xref ref-type="bibr" rid="CR24">24</xref>]</p></td><td><p>28 (15/13)</p></td><td><p>DB, Israel</p></td><td><p>30.3 (2.8)/28.7 (2.9)</p></td><td><p>1.52 (0.55)/1.21 (0.45)</p></td><td><p>10/5, 5/8</p></td><td><p>35</p></td><td><p>Lactulose</p></td><td><p>1.5 g/kg/day</p></td><td><p>Dextrose</p></td><td><p>NEC, mortality, sepsis, feeding intolerance, and days to reach full enteral feeding</p></td><td><p>Suggest positive prebiotic effects</p></td><td><p>10</p></td><td><p>Mixture solution</p></td></tr><tr><td><p>Modi et al. [<xref ref-type="bibr" rid="CR25">25</xref>]</p></td><td><p>154 (73/81)</p></td><td><p>DB, UK</p></td><td><p>30.0 (0.5)/31.0 (0.5)</p></td><td><p>1.57 (0.88)/1.52 (0.91)</p></td><td><p>48/25, 50/31</p></td><td><p>28</p></td><td><p>scGOS/lcFOS</p></td><td><p>1.2 g/kg/day</p></td><td><p>Formula</p></td><td><p>NEC, mortality, sepsis, feeding intolerance</p></td><td><p>Safe and may benefit enteral tolerance</p></td><td><p>11</p></td><td><p>Formula</p></td></tr><tr><td><p>Kapiki et al. [<xref ref-type="bibr" rid="CR20">20</xref>]</p></td><td><p>56 (36/20)</p></td><td><p>SB, Greece</p></td><td><p>33.4 (1.8)/33.9 (1.3)</p></td><td><p>1.59 (0.33)/1.64 (0.17)</p></td><td><p>16/17, 8/12</p></td><td><p>7</p></td><td><p>scGOS</p></td><td><p>0.6 g/kg/day</p></td><td><p>Maltodextrin</p></td><td><p>Bifidogenic effect, stool characteristics</p></td><td><p>Small quantity of prebiotic is well accepted</p></td><td><p>7</p></td><td><p>Formula</p></td></tr><tr><td><p>Mihatsch et al. [<xref ref-type="bibr" rid="CR26">26</xref>]</p></td><td><p>20 (10/10)</p></td><td><p>DB, Germany</p></td><td><p>27.1 (2.2)/27.6 (3.3)</p></td><td><p>0.89 (0.64)/0.90 (0.69)</p></td><td><p>Not mentioned</p></td><td><p>14</p></td><td><p>scGOS/lcFOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Maltodextrin</p></td><td><p>Stool characteristics</p></td><td><p>Reduce stool viscosity</p></td><td><p>11</p></td><td><p>Formula</p></td></tr><tr><td><p>Boehm et al. [<xref ref-type="bibr" rid="CR27">27</xref>]</p></td><td><p>27 (12/15)</p></td><td><p>SB, Italy</p></td><td><p>31.2 (0.6)/31.4 (0.9)</p></td><td><p>1.59 (0.24)/1.60 (0.32)</p></td><td><p>8/7, 7/5</p></td><td><p>28</p></td><td><p>scGOS/lcFOS</p></td><td><p>1.5 g/kg/day</p></td><td><p>Maltodextrin</p></td><td><p>Stool characteristics</p></td><td><p>More frequent and softer stools</p></td><td><p>8</p></td><td><p>Formula</p></td></tr></tbody></table><table-wrap-foot><p>Values are means (SDs) unless otherwise indicated</p><p><italic>scGOS/lcFOS</italic> short chain galacto-oligosaccharides/long chain fructo-oligosaccharides, <italic>pAOS</italic> pectin-derived acidic oligosaccharides, <italic>DB</italic> double blind, <italic>SB</italic> single blind, <italic>P/C</italic> prebiotic group/control group</p></table-wrap-foot></table-wrap></p><sec id="Sec8"><title>Effects on sepsis</title><p id="Par17">Eleven trials, with 1106 infants, reported sepsis rates. The mean morbidity rate for the infants receiving prebiotics was 17.4% compared with 27.4% in the controls. The results of meta-analysis showed a significant decrease in risk ratio of 0.64 (95% CI: 0.51, 0.78; <italic>P</italic> &lt; 0.001) in the group of preterm infants receiving prebiotic treatment compared with that of the control group, with no significant heterogeneity among studies (<italic>I</italic><sup>2</sup> = 0%, <italic>P</italic> = 0.66) (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>).<fig id="Fig2"><label>Fig. 2</label><caption xml:lang="en"><p>Forest plots of the effects of prebiotics on sepsis (<bold>a</bold>), necrotizing enterocolitis (<bold>b</bold>), mortality (<bold>c</bold>), and feeding intolerance (<bold>d</bold>)</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41430_2018_377_Fig2_HTML.png"/></p></fig></p><p id="Par18">Subgroup analysis (Table <xref rid="Tab2" ref-type="table">2</xref>) showed that prebiotics supplementation could significantly reduce the incidence of sepsis when treatment duration was ≥28 days (<italic>P</italic> &lt; 0.01) compared with &lt;28 days (<italic>P</italic> = 0.15). It is notable that trials that supplied prebiotics using breast milk plus preterm formula milk (<italic>P</italic> &lt; 0.001) as the medium achieved better results in lowering sepsis risk compared with trials using distilled water (<italic>P</italic> = 0.28). It was also found that the effect of prebiotics on reducing sepsis was statistically significant when the quality assessed to be high (<italic>P</italic> &lt; 0.001) compared with moderate quality ones (<italic>P</italic> = 0.17). A significant beneficial effect was also demonstrated in studies using prebiotics with pAOS (<italic>P</italic> &lt; 0.001) compared with prebiotics without pAOS (<italic>P</italic> = 0.13).<table-wrap id="Tab2"><label>Table 2</label><caption xml:lang="en"><p>Subgroup analysis on the effects of probiotics on sepsis, necrotizing enterocolitis, and mortality</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Subgroups</p></th><th colspan="6"><p>Sepsis</p></th><th colspan="6"><p>Necrotizing enterocolitis</p></th><th colspan="6"><p>Mortality</p></th></tr><tr><th><p>Studies, <italic>n</italic></p></th><th><p>Participants, <italic>n</italic></p></th><th><p><italic>I</italic><sup>2</sup></p></th><th><p>Risk ratio</p></th><th><p>95% CI</p></th><th><p><italic>P</italic></p></th><th><p>Studies, <italic>n</italic></p></th><th><p>Participants, <italic>n</italic></p></th><th><p><italic>I</italic><sup>2</sup></p></th><th><p>Risk ratio</p></th><th><p>95% CI</p></th><th><p><italic>P</italic></p></th><th><p>Studies, <italic>n</italic></p></th><th><p>Participants, <italic>n</italic></p></th><th><p><italic>I</italic><sup>2</sup></p></th><th><p>Risk ratio</p></th><th><p>95% CI</p></th><th><p><italic>P</italic></p></th></tr></thead><tbody><tr><td><p>Birth weight</p></td><td/><td/><td/><td/><td/><td><p>0.66</p></td><td/><td/><td/><td/><td/><td><p>0.92</p></td><td/><td/><td/><td/><td/><td><p>0.54</p></td></tr><tr><td><p> &lt;1500 g</p></td><td><p>6</p></td><td><p>652</p></td><td><p>4%</p></td><td><p>0.65</p></td><td><p>0.51, 0.84***</p></td><td/><td><p>3</p></td><td><p>388</p></td><td><p>61%</p></td><td><p>0.77</p></td><td><p>0.29, 2.06</p></td><td/><td><p>3</p></td><td><p>742</p></td><td><p>0%</p></td><td><p> 0.56</p></td><td><p> 0.34, 0.91*</p></td><td/></tr><tr><td><p> 1500- 2500 g</p></td><td><p>5</p></td><td><p>454</p></td><td><p>0%</p></td><td><p>0.59</p></td><td><p>0.39, 0.88**</p></td><td/><td><p>3</p></td><td><p>349</p></td><td><p>0%</p></td><td><p>0.71</p></td><td><p>0.25, 2.07</p></td><td/><td><p>3</p></td><td><p>182</p></td><td><p>3%</p></td><td><p> 1.04</p></td><td><p> 0.15, 7.15</p></td><td/></tr><tr><td><p>Duration of intervention</p></td><td/><td/><td/><td/><td/><td><p> 0.76</p></td><td/><td/><td/><td/><td/><td><p> 0.18</p></td><td/><td/><td/><td/><td/><td><p> 0.17</p></td></tr><tr><td><p> &lt;28 days</p></td><td><p>2</p></td><td><p>242</p></td><td><p>0%</p></td><td><p>0.64</p></td><td><p>0.51, 0.80***</p></td><td/><td><p>2</p></td><td><p>242</p></td><td><p>0%</p></td><td><p>0.39</p></td><td><p>0.13, 1.24</p></td><td/><td><p>2</p></td><td><p>125</p></td><td><p>0%</p></td><td><p> 2.38</p></td><td><p> 0.30, 18.75</p></td><td/></tr><tr><td><p> ≥28 days</p></td><td><p>9</p></td><td><p>864</p></td><td><p>0%</p></td><td><p>0.63</p></td><td><p>0.51, 0.78***</p></td><td/><td><p>4</p></td><td><p>495</p></td><td><p>17%</p></td><td><p>0.97</p></td><td><p>0.51, 1.83</p></td><td/><td><p>4</p></td><td><p>771</p></td><td><p>0%</p></td><td><p> 0.54</p></td><td><p> 0.33, 0.90*</p></td><td/></tr><tr><td><p>Form of prebiotics</p></td><td/><td/><td/><td/><td/><td><p> 0.62</p></td><td/><td/><td/><td/><td/><td><p> 0.6</p></td><td/><td/><td/><td/><td/><td><p> 0.68</p></td></tr><tr><td><p> Milk</p></td><td><p>10</p></td><td><p>1078</p></td><td><p>0%</p></td><td><p>0.64</p></td><td><p>0.52, 0.79***</p></td><td/><td><p>5</p></td><td><p>709</p></td><td><p>34%</p></td><td><p>0.82</p></td><td><p>0.42, 1.62</p></td><td/><td><p>5</p></td><td><p>846</p></td><td><p>0%</p></td><td><p> 0.57</p></td><td><p> 0.35, 0.93*</p></td><td/></tr><tr><td><p> Other</p></td><td><p>1</p></td><td><p>28</p></td><td><p>Not applicable</p></td><td><p>0.43</p></td><td><p>0.09, 1.99</p></td><td/><td><p>1</p></td><td><p>28</p></td><td><p>Not applicable</p></td><td><p>0.43</p></td><td><p>0.04, 4.25</p></td><td/><td><p>1</p></td><td><p>78</p></td><td><p>6%</p></td><td><p>0.92</p></td><td><p> 0.09 9.07</p></td><td/></tr><tr><td><p>Quality of study</p></td><td/><td/><td/><td/><td/><td><p>0.1</p></td><td/><td/><td/><td/><td/><td><p>0.13</p></td><td/><td/><td/><td/><td/><td><p>0.83</p></td></tr><tr><td><p> High</p></td><td><p>8</p></td><td><p>861</p></td><td><p>0%</p></td><td><p>0.55</p></td><td><p>0.42, 0.72***</p></td><td/><td><p>5</p></td><td><p>662</p></td><td><p>0%</p></td><td><p>0.88</p></td><td><p>0.54, 1.43</p></td><td/><td><p>5</p></td><td><p>658</p></td><td><p>8%</p></td><td><p> 0.56</p></td><td><p> 0.29, 1.07</p></td><td/></tr><tr><td><p> Moderate</p></td><td><p>3</p></td><td><p>245</p></td><td><p>0%</p></td><td><p>0.79</p></td><td><p>0.57, 1.11</p></td><td/><td><p>1</p></td><td><p>75</p></td><td><p>Not applicable</p></td><td><p>0.18</p></td><td><p>0.02, 1.33</p></td><td/><td><p>1</p></td><td><p>266</p></td><td><p>0%</p></td><td><p>0.62</p></td><td><p> 0.29, 1.35</p></td><td/></tr><tr><td><p>Dosage</p></td><td/><td/><td/><td/><td/><td><p>0.2</p></td><td/><td/><td/><td/><td/><td><p>0.92</p></td><td/><td/><td/><td/><td/><td><p>0.87</p></td></tr><tr><td><p> &lt;1.5 g/kg/day</p></td><td><p>4</p></td><td><p>568</p></td><td><p>0%</p></td><td><p>0.55</p></td><td><p>0.41, 0.75***</p></td><td/><td><p>3</p></td><td><p>521</p></td><td><p>0%</p></td><td><p>0.7</p></td><td><p>0.39, 1.26</p></td><td/><td><p>3</p></td><td><p>354</p></td><td><p>70%</p></td><td><p> 0.51</p></td><td><p> 0.04, 6.34</p></td><td/></tr><tr><td><p> 1.5 g/kg/day</p></td><td><p>6</p></td><td><p>480</p></td><td><p>0%</p></td><td><p>0.73</p></td><td><p>0.54, 0.98*</p></td><td/><td><p>3</p></td><td><p>216</p></td><td><p>60%</p></td><td><p>0.64</p></td><td><p>0.14, 3.02</p></td><td/><td><p>3</p></td><td><p>570</p></td><td><p>0%</p></td><td><p> 0.64</p></td><td><p> 0.38, 1.07</p></td><td/></tr><tr><td><p>Type of prebiotics</p></td><td/><td/><td/><td/><td/><td><p>0.09</p></td><td/><td/><td/><td/><td/><td><p> 0.06</p></td><td/><td/><td/><td/><td/><td><p>0.83</p></td></tr><tr><td><p> Without pAOS</p></td><td><p>4</p></td><td><p>377</p></td><td><p>0%</p></td><td><p>0.78</p></td><td><p>0.57, 1.07</p></td><td/><td><p>5</p></td><td><p>624</p></td><td><p>0%</p></td><td><p>0.67</p></td><td><p>0.36, 1.06</p></td><td/><td><p>5</p></td><td><p>507</p></td><td><p>34%</p></td><td><p>0.7</p></td><td><p> 0.18, 2.65</p></td><td/></tr><tr><td><p> With pAOS</p></td><td><p>7</p></td><td><p>729</p></td><td><p>0%</p></td><td><p>0.54</p></td><td><p>0.41, 0.72***</p></td><td/><td><p>1</p></td><td><p>113</p></td><td><p>Not applicable</p></td><td><p>1.76</p></td><td><p>0.68, 4.51</p></td><td/><td><p>1</p></td><td><p>417</p></td><td><p>0%</p></td><td><p> 0.59</p></td><td><p> 0.34, 1.02</p></td><td/></tr></tbody></table><table-wrap-foot><p>*<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec9"><title>Effects on NEC</title><p id="Par19">Six trials, with 737 infant included, presented the morbidity rate of NEC. The mean NEC rate in the prebiotics intervention and control group was 8.2% and 11.2%, respectively. The meta-analysis showed a non-significant risk ratio of 0.79 (95% CI: 0.44, 1.44; <italic>P</italic> = 0.44) between the two groups administered prebiotics and placebo. The heterogeneity of trials was not significant (<italic>I</italic><sup>2</sup> = 21%, <italic>P</italic> = 0.27) (Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). No significant difference was found between the two groups in morbidity rate of NEC, considering birth weight, treatment duration, form of prebiotics, quality of studies, dosage, and the administration of pAOS (Table <xref rid="Tab2" ref-type="table">2</xref>).</p></sec><sec id="Sec10"><title>Effects on mortality</title><p id="Par20">Nine trials, including 924 participants, reported the mortality rates of preterm infants. The mean death rate in the infants receiving prebiotics was 5.4% vs. 9.7% in the controls. The meta-analysis showed a significantly lower risk ratio of 0.58 (95% CI: 0.36, 0.94; <italic>P</italic> &lt; 0.001) in the prebiotics intervention infants compared with the infants receiving the placebo. The heterogeneity of trials was not significant (<italic>I</italic><sup>2</sup> = 0%, <italic>P</italic> = 0.62) (Fig. <xref rid="Fig2" ref-type="fig">2c</xref>).</p><p id="Par21">Subgroup analysis (Table <xref rid="Tab2" ref-type="table">2</xref>) showed that the prebiotics supplementation could significantly reduce the morbidity rate of sepsis when treatment duration was 28 days or more (<italic>P</italic> &lt; 0.05) compared with infants receiving prebiotics less than 28 days (<italic>P</italic> = 0.41). The trials administering prebiotics, along with a combination of breast milk and preterm formula (<italic>P</italic> &lt; 0.05), had a greater effect on mortality compared with trials that used distilled water (<italic>P</italic> = 0.95). The results also showed that prebiotics treatment had a greater effect on reducing the death rate in trials with high quality (<italic>P</italic> &lt; 0.001) compared with that of moderate quality (<italic>P</italic> = 0.17). In addition, prebiotics treatment had a significant effect on preterm infants with a birth weight less than 1500 g (<italic>P</italic> &lt; 0.05) but not with preterm infants with a birth weight ≥1500 g (<italic>P</italic> = 0.97).</p></sec><sec id="Sec11"><title>Effects on feeding intolerance</title><p id="Par22">Four trials, involving 413 infants, reported the incidence of infant feeding intolerance. The mean feeding intolerance rate in infants administered prebiotics was 7.4% compared with 13.4% in controls. There was a non-significant risk ratio of 0.87 (95% CI: 0.52, 1.45; <italic>P</italic> = 0.60) between the infants receiving the prebiotics intervention compared to the placebo. The heterogeneity of trials was not significant (<italic>I</italic><sup>2</sup> = 0%, <italic>P</italic> = 0.34) (Fig. <xref rid="Fig2" ref-type="fig">2d</xref>). No significant difference in reducing the incidence of feeding intolerance was found by subgroup analysis, considering birth weight, treatment duration, form of prebiotics, quality of studies, dosage, and the administration of pAOS.</p></sec><sec id="Sec12"><title>Effects on time to achieve full enteral feeding</title><p id="Par23">Six studies, including 576 infant participants, measured time to achieve full enteral feeding. The results of meta-analysis showed a significantly shorter time to achieve full enteral feeding in the prebiotic group when compared with the control group (MD −0.99, 95% CI: −1.15, 0.83, <italic>P</italic> &lt; 0.001). The heterogeneity of included trials was not significant (<italic>I</italic><sup>2</sup> = 0%, <italic>P</italic> = 0.85) (Fig. <xref rid="Fig3" ref-type="fig">3a</xref>). Subgroup analysis (Table <xref rid="Tab3" ref-type="table">3</xref>) indicated that trials that administered prebiotics along with a combination of human breast milk and preterm formula (<italic>P</italic> &lt; 0.05) tended to be more effective compared with the trial using distilled water (<italic>P</italic> = 1). The results also showed that the effect of prebiotics on reducing time to full enteral feeding was statistically significant in trials of high quality (<italic>P</italic> &lt; 0.001) compared to trials of moderate quality (<italic>P</italic> = 0.39). One study [<xref ref-type="bibr" rid="CR10">10</xref>] with a 14-day intervention showed no significant difference between groups using prebiotics or not (<italic>P</italic> = 0.22). Five studies [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] showed that the infant receiving prebiotics spent less time in achieving full enteral feeding compared to the controls (<italic>P</italic> &lt; 0.01).<fig id="Fig3"><label>Fig. 3</label><caption xml:lang="en"><p>Forest plots of the effects of prebiotics on time to full enteral feeding (<bold>a</bold>), length of hospital stay (<bold>b</bold>), and stool frequency (<bold>c</bold>)</p></caption><p><graphic specific-use="HTML" mime-subtype="PNG" xlink:href="MediaObjects/41430_2018_377_Fig3_HTML.png"/></p></fig><table-wrap id="Tab3"><label>Table 3</label><caption xml:lang="en"><p>Subgroup analysis on the effects of probiotics on time to full enteral feeding, length of hospital stay, and stool frequency</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"><p>Subgroups</p></th><th colspan="6"><p>Time to full enteral feeding</p></th><th colspan="6"><p>Length of hospital stay</p></th><th colspan="6"><p>Stool frequency</p></th></tr><tr><th><p>Studies, <italic>n</italic></p></th><th><p>Participants, <italic>n</italic></p></th><th><p><italic>I</italic><sup>2</sup></p></th><th><p>Mean difference</p></th><th><p>95% CI</p></th><th><p><italic>P</italic></p></th><th><p>Studies, <italic>n</italic></p></th><th><p>Participants, <italic>n</italic></p></th><th><p><italic>I</italic><sup>2</sup></p></th><th><p>Mean difference</p></th><th><p>95% CI</p></th><th><p><italic>P</italic></p></th><th><p>Studies, <italic>n</italic></p></th><th><p>Participants, <italic>n</italic></p></th><th><p><italic>I</italic><sup>2</sup></p></th><th><p>Mean difference</p></th><th><p>95% CI</p></th><th><p><italic>P</italic></p></th></tr></thead><tbody><tr><td><p>Birth weight</p></td><td/><td/><td/><td/><td/><td><p>0.64</p></td><td/><td/><td/><td/><td/><td><p>0.39</p></td><td/><td/><td/><td/><td/><td><p>0.04</p></td></tr><tr><td><p> &lt;1500 g</p></td><td><p>5</p></td><td><p>594</p></td><td><p>94%</p></td><td><p>−1.8</p></td><td><p>−5.21, 1.61</p></td><td/><td><p>6</p></td><td><p>658</p></td><td><p>80%</p></td><td><p>−6.6</p></td><td><p>−10.03, −3.08***</p></td><td/><td><p>3</p></td><td><p>183</p></td><td><p>0%</p></td><td><p>0.34</p></td><td><p> 0.10, 0.58***</p></td><td/></tr><tr><td><p> 1500–2500 g</p></td><td><p>2</p></td><td><p>182</p></td><td><p>0%</p></td><td><p>−1</p></td><td><p>−1.16, −0.84</p></td><td/><td><p>2</p></td><td><p>75</p></td><td><p>17%</p></td><td><p>−1.07</p></td><td><p>−13.05, 10.91</p></td><td/><td><p>3</p></td><td><p>111</p></td><td><p>0%</p></td><td><p> 0.74</p></td><td><p> 0.44, 1.05***</p></td><td/></tr><tr><td><p>Duration of intervention</p></td><td/><td/><td/><td/><td/><td><p> 0.99</p></td><td/><td/><td/><td/><td/><td><p>0.55</p></td><td/><td/><td/><td/><td/><td><p>0.55</p></td></tr><tr><td><p> &lt;28 days</p></td><td><p>1</p></td><td><p>75</p></td><td><p>Not applicable</p></td><td><p>−1.5</p></td><td><p>−3.88, 0.88</p></td><td/><td><p>2</p></td><td><p>175</p></td><td><p>73%</p></td><td><p>−6.95</p></td><td><p>−11.51, −1.68***</p></td><td/><td><p>3</p></td><td><p>126</p></td><td><p>0%</p></td><td><p>0.63</p></td><td><p> 0.32, 0.95***</p></td><td/></tr><tr><td><p> ≥28 days</p></td><td><p>6</p></td><td><p>701</p></td><td><p>98%</p></td><td><p>−1.47</p></td><td><p>−4.29, 1.36</p></td><td/><td><p>6</p></td><td><p>558</p></td><td><p>85%</p></td><td><p>−3.87</p></td><td><p>−11.38, 3.64</p></td><td/><td><p>3</p></td><td><p>168</p></td><td><p>40%</p></td><td><p>0.48</p></td><td><p> 0.11, 0.86</p></td><td/></tr><tr><td><p>Form of prebiotics</p></td><td/><td/><td/><td/><td><p>0.49</p></td><td/><td/><td/><td/><td/><td/><td><p> 0.12</p></td><td/><td/><td/><td/><td/><td><p> 0.48</p></td></tr><tr><td><p> Milk</p></td><td><p>6</p></td><td><p>748</p></td><td><p>98%</p></td><td><p>−1.67</p></td><td><p>−4.43, 1.08</p></td><td/><td><p>6</p></td><td><p>655</p></td><td><p>88%</p></td><td><p>−3.4</p></td><td><p>−9.71, 2.91</p></td><td/><td><p>4</p></td><td><p>216</p></td><td><p>46%</p></td><td><p>0.6</p></td><td><p> 0.27, 0.93***</p></td><td/></tr><tr><td><p> Other</p></td><td><p>1</p></td><td><p>28</p></td><td><p>Not applicable</p></td><td><p>0</p></td><td><p>−3.88, 3.88</p></td><td/><td><p>2</p></td><td><p>78</p></td><td><p>0%</p></td><td><p>−8.65</p></td><td><p>−10.35, −6.94***</p></td><td/><td><p>2</p></td><td><p>78</p></td><td><p>0%</p></td><td><p>0.4</p></td><td><p> −0.05, 0.85***</p></td><td/></tr><tr><td><p>Quality of study</p></td><td/><td/><td/><td/><td/><td><p>0.58</p></td><td/><td/><td/><td/><td/><td><p>0.13</p></td><td/><td/><td/><td/><td/><td><p>0.03</p></td></tr><tr><td><p> High</p></td><td><p>5</p></td><td><p>608</p></td><td><p>99%</p></td><td><p>−1.76</p></td><td><p>−4.92, 1.4</p></td><td/><td><p>5</p></td><td><p>438</p></td><td><p>86%</p></td><td><p>−6.98</p></td><td><p>−11.31, −2.65***</p></td><td/><td><p>4</p></td><td><p>211</p></td><td><p>0%</p></td><td><p>0.34</p></td><td><p> 0.11, 0.58***</p></td><td/></tr><tr><td><p> Moderate</p></td><td><p>2</p></td><td><p>168</p></td><td><p>0%</p></td><td><p>−0.74</p></td><td><p>−2.4, 0.93</p></td><td/><td><p>3</p></td><td><p>295</p></td><td><p>0%</p></td><td><p>−2.44</p></td><td><p>−6.41, 1.52</p></td><td/><td><p>2</p></td><td><p>83</p></td><td><p>0%</p></td><td><p>0.79</p></td><td><p> 0.47, 1.12***</p></td><td/></tr><tr><td><p>Dosage</p></td><td/><td/><td/><td/><td/><td><p>0.24</p></td><td/><td/><td/><td/><td/><td><p>0.89</p></td><td/><td/><td/><td/><td/><td><p>0.16</p></td></tr><tr><td><p> &lt;1.5 g/kg/day</p></td><td><p>2</p></td><td><p>354</p></td><td><p>100%</p></td><td><p>−3.49</p></td><td><p>−8.39, 1.41</p></td><td/><td><p>2</p></td><td><p>247</p></td><td><p>95%</p></td><td><p>−5.75</p></td><td><p>−18.48, 6.98</p></td><td/><td><p>1</p></td><td><p>56</p></td><td><p>Not applicable</p></td><td><p>0.75</p></td><td><p> 0.34, 1.16***</p></td><td/></tr><tr><td><p> 1.5 g/kg/day</p></td><td><p>5</p></td><td><p>422</p></td><td><p>0%</p></td><td><p>−0.46</p></td><td><p>−1.65, 0.73</p></td><td/><td><p>6</p></td><td><p>486</p></td><td><p>49%</p></td><td><p>−4.8</p></td><td><p>−8.78, −0.82*</p></td><td/><td><p>5</p></td><td><p>238</p></td><td><p>0%</p></td><td><p>0.42</p></td><td><p> 0.21, 0.64***</p></td><td/></tr><tr><td><p>Type of prebiotics</p></td><td/><td/><td/><td/><td/><td><p>0.27</p></td><td/><td/><td/><td/><td/><td><p>0.03</p></td><td/><td/><td/><td/><td/><td><p>0.06</p></td></tr><tr><td><p> Without pAOS</p></td><td><p>4</p></td><td><p>457</p></td><td><p>99%</p></td><td><p>−2.29</p></td><td><p>−5.8, 1.23</p></td><td/><td><p>5</p></td><td><p>389</p></td><td><p>92%</p></td><td><p>−10.81</p></td><td><p>−19.62, −2.01*</p></td><td/><td><p>5</p></td><td><p>181</p></td><td><p>0%</p></td><td><p>0.66</p></td><td><p> 0.41, 0.92***</p></td><td/></tr><tr><td><p> With pAOS</p></td><td><p>3</p></td><td><p>319</p></td><td><p>0%</p></td><td><p>−0.13</p></td><td><p>−1.6, 1.33</p></td><td/><td><p>3</p></td><td><p>283</p></td><td><p>0%</p></td><td><p>−7.16</p></td><td><p>−6.63, 4.95</p></td><td/><td><p>1</p></td><td><p>113</p></td><td><p>Not applicable</p></td><td><p>0.3</p></td><td><p> 0.02, 0.58*</p></td><td/></tr></tbody></table><table-wrap-foot><p>*<italic>P</italic> &lt; 0.05, **<italic>P</italic> &lt; 0.01, ***<italic>P</italic> &lt; 0.001</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec13"><title>Effects on length of hospital stay</title><p id="Par24">Eight trials, comprising 733 infant participants, reported the length of hospital stay. Data from six studies [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR24">24</xref>] showed that the infants received prebiotic supplement had a shorter length of hospital stay, while two studies [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] did not observe any significant difference on this variable. The meta-analysis showed a significant reduction in length of hospital stay of 0.58 (MD −5.18, 95% CI: −8.94, −1.11, <italic>P</italic> = 0.007) (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>) in the prebiotics intervention infants compared with the infants receiving the placebo. The heterogeneity of trials was significant (<italic>I</italic><sup>2</sup> = 83%, <italic>P</italic> &lt; 0.001), and subgroup analysis (Table <xref rid="Tab3" ref-type="table">3</xref>) did not improve the heterogeneity. We also performed a sensitivity analysis to address the heterogeneity and confirm the stability of our results. The cumulative sensitivity test also demonstrated the total effect was not due to any single study.</p></sec><sec id="Sec14"><title>Effects on stool frequency</title><p id="Par25">Six studies with 294 infant participants measured stool frequency. The stool frequency in the prebiotic group was significantly higher when compared to the control group (MD 0.52, 95% CI: 0.3, 0.73, <italic>P</italic> &lt; 0.001). The heterogeneity of trials was not significant (<italic>I</italic><sup>2</sup> = 13%, <italic>P</italic> = 0.33) (Fig. <xref rid="Fig3" ref-type="fig">3c</xref>). Studies with prebiotics administered via a combination of breast and formula milk (<italic>P</italic> &lt; 0.001) showed a significantly higher stool frequency compared with studies that used other mediums (<italic>P</italic> = 0.08). In addition, subgroup analysis showed no significant difference in stool frequency, considering birth weight, treatment duration, quality of studies, and dosage (Table <xref rid="Tab3" ref-type="table">3</xref>).</p></sec><sec id="Sec15"><title>Publication bias</title><p id="Par26">The visual inspection of each funnel plots showed no obvious publication bias associated with the efficacy of prebiotics on infection, feeding intolerance, time to full enteral feeding, mortality, NEC, stool frequency, and length of stay in hospital. This conclusion was supported by results from the Egger’s test (sepsis: <italic>P</italic> = 0.80, NEC: <italic>P</italic> = 0.73, mortality: <italic>P</italic> = 0.73, time to full enteral feeding: <italic>P</italic> = 0.63, length of hospital stay: <italic>P</italic> = 0.08, stool frequency: <italic>P</italic> = 0.32) (Table <xref rid="Tab4" ref-type="table">4</xref>), which showed no statistically significant evidence of publication bias.<table-wrap id="Tab4"><label>Table 4</label><caption xml:lang="en"><p>Publication bias illustrated by Egger test</p></caption><table frame="hsides" rules="groups"><thead><tr><th><p>Variable name</p></th><th><p><italic>t</italic> (95% CI)</p></th><th><p><italic>P</italic></p></th></tr></thead><tbody><tr><td><p>Sepsis</p></td><td><p>0.26 (−2.42, 1.93)</p></td><td><p>0.8</p></td></tr><tr><td><p>NEC</p></td><td><p>0.36 (−3.90, 3.99)</p></td><td><p>0.73</p></td></tr><tr><td><p>Mortality</p></td><td><p>0.36 (−3.90, 3.99)</p></td><td><p>0.73</p></td></tr><tr><td><p>Time to full enteral feeding</p></td><td><p>0.52 (−11.27, 7.49)</p></td><td><p>0.63</p></td></tr><tr><td><p>Length of hospital stay</p></td><td><p>2.11 (−0.33, 4.51)</p></td><td><p>0.08</p></td></tr><tr><td><p>Stool frequency</p></td><td><p>1.13 (−2.18, 5.16)</p></td><td><p>0.32</p></td></tr></tbody></table></table-wrap></p></sec></sec><sec id="Sec16" sec-type="discussion"><title>Discussion</title><p id="Par27">Overall, the results, based on our meta-analysis, showed that prebiotics can improve the health of preterm infants, including decreasing the incidence of sepsis and death, reducing time to achieve full enteral feeding and hospital stay, increasing the stool frequency. Besides, the effects of prebiotics on the risk of feeding intolerance and NEC were not statistically significant. Despite improvements in NICU healthcare provided by experienced neonatologists, the morbidity rate of sepsis and NEC remain high in preterm infants [<xref ref-type="bibr" rid="CR28">28</xref>]. This is concerning because a reduction in the morbidity rate of sepsis and NEC can significantly reduce the complications and death rate associated with premature delivery.</p><p id="Par28">Our results showed prebiotics supplementation could reduce the risk of NEC, which is consistent with previous published studies [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR30">30</xref>]. However, unlike our study, previous reviews included less trials and had smaller sample sizes which reduced the power to assess for clinically important main outcomes. Our study included more RCT trials focused on medical complications and key variables. We also conducted subgroup analyses to reveal the effect of prebiotics with or without pAOS, and therefore, the effect of pAOS on reducing sepsis could be indicated.</p><p id="Par29">The mechanism of prebiotics in decreasing the risk of sepsis and mortality might be related to preventing colonization of pathogenic bacteria and the overgrowth of opportunistic pathogens [<xref ref-type="bibr" rid="CR31">31</xref>]. In addition, prebiotics can improve intestinal motility and intestinal permeability of preterm infants, leading to a better intestinal integrity of the epithelial surface. The combine action between the restrain of pathogens and inhibition of pathogens adhere to the epithelial surface may also be involved in promoting the resistance of preterm infants to endogenous infections [<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>].</p><p id="Par30">Subgroup analyses showed the beneficial effects of prebiotics on lowering the morbidity rate of sepsis and death might be due to the effects of preterm infants’ gestational age, prebiotic forms, and prebiotic types (added pAOS). Potential mechanisms by which prebiotics protect preterm infants from high risk of sepsis may relate to increasing the barrier to prevent the pathogenic bacteria and toxins from migrating across the intestinal mucosa, promoting a competitive exclusion of potential pathogens. Furthermore, prebiotics could modify hosts’ response to bacterial toxins and enhance their immune responses.</p><p id="Par31">In our study, we found newborns with a gestational age &lt;28 weeks would benefit less from prebiotic supplementation. The immune system, intestinal mucosa barrier as well as a distinct gut microbiota of these very low birth weight infants are less developed [<xref ref-type="bibr" rid="CR5">5</xref>]. Due to excessive antibiotic use in these high-risk infants, antibiotic treatment before and after birth may have dramatically affected the composition of their gut microbiota, and caused intestinal dysbacteriosis [<xref ref-type="bibr" rid="CR34">34</xref>–<xref ref-type="bibr" rid="CR36">36</xref>]. The imbalance needs to be addressed through the use of probiotics [<xref ref-type="bibr" rid="CR37">37</xref>] or synbiotics [<xref ref-type="bibr" rid="CR38">38</xref>–<xref ref-type="bibr" rid="CR40">40</xref>]. Using prebiotics alone may do little to re-establish micro-ecological balance after excessive antibiotic exposure [<xref ref-type="bibr" rid="CR41">41</xref>–<xref ref-type="bibr" rid="CR43">43</xref>]. Most of the trials included in our study supplemented prebiotics by adding oligosaccharide into breast milk or formula [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>–<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>–<xref ref-type="bibr" rid="CR23">23</xref>], while other trials used distilled water as a medium [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR24">24</xref>]. In our study, trials using breast milk or formula as a medium to supply prebiotics had significant pooled effects on reducing sepsis. This effect is in line with the ability of pAOS, which are designed to act as receptors-analogs, preventing pathogens from adhering to the epithelial surface of the digestive tract [<xref ref-type="bibr" rid="CR44">44</xref>]. The heterogeneity among the trials included was not significant, indicating that the effect of breast milk intake on lowering the morbidity rate of sepsis was consistent. Beyond nutritional components, breast milk contains some important bioactive substances such as microbes, oligosaccharides, cytokines, immunoglobulins, and proteins, which directly influence the development of infants and shape their intestinal microbiota colonization [<xref ref-type="bibr" rid="CR45">45</xref>]. These bioactive substances are considered not only protective but also stimulate the development and maturation of the immature immune system [<xref ref-type="bibr" rid="CR46">46</xref>]. This could explain why we observed better results in trials using a combination of breast milk or formula as a medium to supply prebiotics rather than trials that used distilled water.</p><p id="Par32">Healthcare for preterm infants face many problems in feeding, because of the increased morbidity rate of NEC and feeding intolerance, full enteral feeding is often difficult. The pooled effects based on our meta-analysis showed a notable reduced time to enteral feeding with the administration of prebiotics to preterm infants. Prebiotic supplement increases the abundances of prebiotics, such as <italic>bifidobacteria</italic> and <italic>lactobacillus</italic>, and reduce the abundance of potential pathogenic bacteria in gut microbiota of preterm infants [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. The colonization of beneficial bacteria can improve stool frequency and consistency, which in turn promote the enteral feeding tolerance and shorten the time to achieve full enteral feeding in preterm infants [<xref ref-type="bibr" rid="CR26">26</xref>].</p><p id="Par33">There were no significant differences on two items, including the morbidity rate of NEC and feeding intolerance. The morbidity of NEC could be explained by active medical intervention in the NICUs addressed infection risks such as proper fasting and parenteral nutrition [<xref ref-type="bibr" rid="CR3">3</xref>]. The effectiveness of early detection and prevention of NEC varied from rural hospitals with relative poor medical technology to teaching hospitals in cities [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Most of the 18 trials were conducted in teaching hospitals, in which early diagnosis and prophylactic treatment can be made by experienced clinicians. The lack of effect of prebiotics on reducing the development of NEC could also be partially due to the fact that oligosaccharides employed in the trials (scGOS, lcFOS, and pAOS) have completely different structures compared to the oligosaccharides of human milk [<xref ref-type="bibr" rid="CR46">46</xref>], especially when they are applied to preterm infants who have a different microbiota system than full-term infants [<xref ref-type="bibr" rid="CR49">49</xref>]. In consideration of the immature gastrointestinal tract and immune system of preterm infants, prebiotic supplementation should be administered with caution [<xref ref-type="bibr" rid="CR9">9</xref>]. With regards to feeding intolerance, subgroup analysis suggests that prebiotics used in these trials were well tolerated by preterm infants. According to two studies [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR16">16</xref>], the maximum supplementation dose of 1.5 g/kg/day appears to be effective and safe.</p><sec id="Sec17"><title>Limitation</title><p id="Par34">The limitation of our study is that all the variables reflect the micro-ecological balance in intestinal flora indirectly. Some early trials measured the number of bacterial colonies by cultivation which is subject to error and is potentially heterogeneous. With the development of second-generation sequencing, further RCTs are required to clarify the stains and their proportion in stool using 16S RNA sequencing or metagenomic sequencing. Only in this way can we reveal the mechanism of prebiotics on intestinal flora and preterm infant’s health directly.</p></sec><sec id="Sec18"><title>Clinical implications</title><p id="Par35">The results of our study showed that prebiotics could provide significant benefits for preterm infant, including reductions of the incidence of sepsis, mortality, and time to achieve full enteral feeding. Considering these outcomes, the prebiotics supplement in NICUs would be highly beneficial for preterm infants. Prebiotics administration did little in reducing NEC and sepsis in very preterm infants. A new approach in gut microbiota management of infants is the administration of synbiotics, by combining the effect of probiotics and prebiotics. The growth of added live beneficial bacteria (probiotics) may be stimulated by specific substrates (prebiotics), which could improve the survival rate of the probiotics and provide readily substrates for fermentation. As one of the non-human milk oligosaccharides, pAOS have been produced to mimic human milk oligosaccharides. The Th2-type immune response could be attenuated better by pAOS than neutral oligosaccharides (scGOS and lcFOS) alone [<xref ref-type="bibr" rid="CR50">50</xref>].</p><p id="Par36">Overall, the results of our study showed that prebiotics administration is effective in reducing the prevalence rates of sepsis and death, shortens the time to achieve full enteral feeding and hospital stay, and increases the stool frequency. Prebiotics supplement is more effective on infants ≥28 weeks, especially when administered in accompany with breast milk plus formula, added pAOS. Prebiotics may provide a novel approach to reduce the high incidence of complications caused by sepsis and improve the health of preterm infants.</p></sec></sec></body><back><ack><sec id="FPar1"><title>Funding</title><p id="Par37">This work was supported by Beijing Natural Science Foundation (Grant No. S160003).</p></sec></ack><sec sec-type="author-contribution"><title>Author contributions</title><p>JS and CY designed the study. CC and JS collected the data, conducted the statistical analysis, and wrote the manuscript. NB and CL reviewed, edited, and revised the manuscript. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.</p></sec><sec sec-type="ethics-statement"><title>Compliance with ethical standards</title><sec id="FPar2" sec-type="COI-statement"><title>Conflict of interest</title><p id="Par38">The authors declare that they have no conflict of interest.</p></sec></sec><ref-list id="Bib1"><title>References</title><ref-list><ref id="CR1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>BJ</given-names></name><name><surname>Hansen</surname><given-names>NI</given-names></name><name><surname>Bell</surname><given-names>EF</given-names></name><name><surname>Walsh</surname><given-names>MC</given-names></name><name><surname>Carlo</surname><given-names>WA</given-names></name><name><surname>Shankaran</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Trends in care practices, morbidity, and mortality of extremely preterm neonates, 1993–2012</article-title><source>JAMA</source><year>2015</year><volume>314</volume><fpage>1039</fpage><lpage>51</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XkslKjsA%3D%3D</pub-id><pub-id pub-id-type="pmid">26348753</pub-id><pub-id pub-id-type="pmcid">4787615</pub-id></mixed-citation></ref><ref id="CR2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horbar</surname><given-names>JD</given-names></name><name><surname>Edwards</surname><given-names>EM</given-names></name><name><surname>Greenberg</surname><given-names>LT</given-names></name><name><surname>Morrow</surname><given-names>KA</given-names></name><name><surname>Soll</surname><given-names>RF</given-names></name><name><surname>Buus-Frank</surname><given-names>ME</given-names></name><etal/></person-group><article-title xml:lang="en">Variation in performance of neonatal intensive care units in the United States</article-title><source>JAMA Pediatr</source><year>2017</year><volume>171</volume><pub-id pub-id-type="pmid">28068438</pub-id></mixed-citation></ref><ref id="CR3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>HC</given-names></name><name><surname>Wu</surname><given-names>SF</given-names></name><name><surname>Underwood</surname><given-names>M</given-names></name></person-group><article-title xml:lang="en">Necrotizing enterocolitis</article-title><source>N Engl J Med</source><year>2011</year><volume>364</volume><fpage>1878</fpage><lpage>9</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXlvF2iu7k%3D</pub-id><pub-id pub-id-type="pmid">21568003</pub-id></mixed-citation></ref><ref id="CR4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stoll</surname><given-names>BJ</given-names></name><name><surname>Hansen</surname><given-names>N</given-names></name><name><surname>Fanaroff</surname><given-names>AA</given-names></name><name><surname>Wright</surname><given-names>LL</given-names></name><name><surname>Carlo</surname><given-names>WA</given-names></name><name><surname>Ehrenkranz</surname><given-names>RA</given-names></name><etal/></person-group><article-title xml:lang="en">Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network</article-title><source>Pediatrics</source><year>2002</year><volume>110</volume><fpage>285</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">12165580</pub-id></mixed-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>C</given-names></name><name><surname>Stigum</surname><given-names>H</given-names></name><name><surname>Valeur</surname><given-names>J</given-names></name><name><surname>Iszatt</surname><given-names>N</given-names></name><name><surname>Lenters</surname><given-names>V</given-names></name><name><surname>Peddada</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Preterm infants have distinct microbiomes not explained by mode of delivery, breastfeeding duration or antibiotic exposure</article-title><source>Int J Epidemiol</source><year>2018</year><volume>47</volume><fpage>1658</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">29688458</pub-id></mixed-citation></ref><ref id="CR6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saleem</surname><given-names>B</given-names></name><name><surname>Okogbule-Wonodi</surname><given-names>AC</given-names></name><name><surname>Fasano</surname><given-names>A</given-names></name><name><surname>Magder</surname><given-names>LS</given-names></name><name><surname>Ravel</surname><given-names>J</given-names></name><name><surname>Kapoor</surname><given-names>S</given-names></name><etal/></person-group><article-title xml:lang="en">Intestinal barrier maturation in very low birthweight infants: relationship to feeding and antibiotic exposure</article-title><source>J Pediatr</source><year>2017</year><volume>183</volume><fpage>31</fpage><lpage>6</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXhvFeju7o%3D</pub-id><pub-id pub-id-type="pmid">28159311</pub-id><pub-id pub-id-type="pmcid">5367935</pub-id></mixed-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eiwegger</surname><given-names>T</given-names></name><name><surname>Stahl</surname><given-names>B</given-names></name><name><surname>Haidl</surname><given-names>P</given-names></name><name><surname>Schmitt</surname><given-names>J</given-names></name><name><surname>Boehm</surname><given-names>G</given-names></name><name><surname>Dehlink</surname><given-names>E</given-names></name><etal/></person-group><article-title xml:lang="en">Prebiotic oligosaccharides: in vitro evidence for gastrointestinal epithelial transfer and immunomodulatory properties</article-title><source>Pediatr Allergy Immunol</source><year>2010</year><volume>21</volume><fpage>1179</fpage><lpage>88</lpage><pub-id pub-id-type="pmid">20444147</pub-id></mixed-citation></ref><ref id="CR8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacquot</surname><given-names>A</given-names></name><name><surname>Neveu</surname><given-names>D</given-names></name><name><surname>Aujoulat</surname><given-names>F</given-names></name><name><surname>Mercier</surname><given-names>G</given-names></name><name><surname>Marchandin</surname><given-names>H</given-names></name><name><surname>Jumas-Bilak</surname><given-names>E</given-names></name><etal/></person-group><article-title xml:lang="en">Dynamics and clinical evolution of bacterial gut microflora in extremely premature patients</article-title><source>J Pediatr</source><year>2011</year><volume>158</volume><fpage>390</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">20961563</pub-id></mixed-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frost</surname><given-names>BL</given-names></name><name><surname>Modi</surname><given-names>BP</given-names></name><name><surname>Jaksic</surname><given-names>T</given-names></name><name><surname>Caplan</surname><given-names>MS</given-names></name></person-group><article-title xml:lang="en">New medical and surgical insights into neonatal necrotizing enterocolitis: a review</article-title><source>JAMA Pediatr</source><year>2017</year><volume>171</volume><fpage>83</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">27893069</pub-id></mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armanian</surname><given-names>AM</given-names></name><name><surname>Sadeghnia</surname><given-names>A</given-names></name><name><surname>Hoseinzadeh</surname><given-names>M</given-names></name><name><surname>Mirlohi</surname><given-names>M</given-names></name><name><surname>Feizi</surname><given-names>A</given-names></name><name><surname>Salehimehr</surname><given-names>N</given-names></name><etal/></person-group><article-title xml:lang="en">The effect of neutral oligosaccharides on reducing the incidence of necrotizing enterocolitis in preterm infants: a randomized clinical trial</article-title><source>Int J Prev Med</source><year>2014</year><volume>5</volume><fpage>1387</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">25538834</pub-id><pub-id pub-id-type="pmcid">4274545</pub-id></mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armanian</surname><given-names>AM</given-names></name><name><surname>Barekatain</surname><given-names>B</given-names></name><name><surname>Hoseinzadeh</surname><given-names>M</given-names></name><name><surname>Salehimehr</surname><given-names>N</given-names></name></person-group><article-title xml:lang="en">Prebiotics for the management of hyperbilirubinemia in preterm neonates</article-title><source>J Matern Fetal Neonatal Med</source><year>2016</year><volume>29</volume><fpage>3009</fpage><lpage>13</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXhvFOmtLrJ</pub-id><pub-id pub-id-type="pmid">26513278</pub-id></mixed-citation></ref><ref id="CR12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armanian</surname><given-names>AM</given-names></name><name><surname>Sadeghnia</surname><given-names>A</given-names></name><name><surname>Hoseinzadeh</surname><given-names>M</given-names></name><name><surname>Mirlohi</surname><given-names>M</given-names></name><name><surname>Feizi</surname><given-names>A</given-names></name><name><surname>Salehimehr</surname><given-names>N</given-names></name><etal/></person-group><article-title xml:lang="en">The effect of neutral oligosaccharides on fecal microbiota in premature infants fed exclusively with breast milk: a randomized clinical trial</article-title><source>J Res Pharm Pract</source><year>2016</year><volume>5</volume><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXmtFymurY%3D</pub-id><pub-id pub-id-type="pmid">26985433</pub-id><pub-id pub-id-type="pmcid">4776544</pub-id></mixed-citation></ref><ref id="CR13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerbeek</surname><given-names>EA</given-names></name><name><surname>van den Berg</surname><given-names>JP</given-names></name><name><surname>Lafeber</surname><given-names>HN</given-names></name><name><surname>Fetter</surname><given-names>WP</given-names></name><name><surname>Boehm</surname><given-names>G</given-names></name><name><surname>Twisk</surname><given-names>JW</given-names></name><etal/></person-group><article-title xml:lang="en">Neutral and acidic oligosaccharides in preterm infants: a randomized, double-blind, placebo-controlled trial</article-title><source>Am J Clin Nutr</source><year>2010</year><volume>91</volume><fpage>679</fpage><lpage>86</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3cXisFynurs%3D</pub-id><pub-id pub-id-type="pmid">20032496</pub-id></mixed-citation></ref><ref id="CR14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Westerbeek</surname><given-names>EA</given-names></name><name><surname>Hensgens</surname><given-names>RL</given-names></name><name><surname>Mihatsch</surname><given-names>WA</given-names></name><name><surname>Boehm</surname><given-names>G</given-names></name><name><surname>Lafeber</surname><given-names>HN</given-names></name><name><surname>van Elburg</surname><given-names>RM</given-names></name></person-group><article-title xml:lang="en">The effect of neutral and acidic oligosaccharides on stool viscosity, stool frequency and stool pH in preterm infants</article-title><source>Acta Paediatr</source><year>2011</year><volume>100</volume><fpage>1426</fpage><lpage>31</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXhs1SnsrvP</pub-id><pub-id pub-id-type="pmid">21449921</pub-id></mixed-citation></ref><ref id="CR15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Niele</surname><given-names>N</given-names></name><name><surname>van Zwol</surname><given-names>A</given-names></name><name><surname>Westerbeek</surname><given-names>EA</given-names></name><name><surname>Lafeber</surname><given-names>HN</given-names></name><name><surname>van Elburg</surname><given-names>RM</given-names></name></person-group><article-title xml:lang="en">Effect of non-human neutral and acidic oligosaccharides on allergic and infectious diseases in preterm infants</article-title><source>Eur J Pediatr</source><year>2013</year><volume>172</volume><fpage>317</fpage><lpage>23</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3sXjtlygu78%3D</pub-id><pub-id pub-id-type="pmid">23132642</pub-id></mixed-citation></ref><ref id="CR16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>JP</given-names></name><name><surname>Westerbeek</surname><given-names>EA</given-names></name><name><surname>van der Klis</surname><given-names>FR</given-names></name><name><surname>Berbers</surname><given-names>GA</given-names></name><name><surname>Lafeber</surname><given-names>HN</given-names></name><name><surname>van Elburg</surname><given-names>RM</given-names></name></person-group><article-title xml:lang="en">Neutral and acidic oligosaccharides supplementation does not increase the vaccine antibody response in preterm infants in a randomized clinical trial</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><pub-id pub-id-type="pmid">23951035</pub-id><pub-id pub-id-type="pmcid">3738516</pub-id></mixed-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>LeCouffe</surname><given-names>NE</given-names></name><name><surname>Westerbeek</surname><given-names>EA</given-names></name><name><surname>van Schie</surname><given-names>PE</given-names></name><name><surname>Schaaf</surname><given-names>VA</given-names></name><name><surname>Lafeber</surname><given-names>HN</given-names></name><name><surname>van Elburg</surname><given-names>RM</given-names></name></person-group><article-title xml:lang="en">Neurodevelopmental outcome during the first year of life in preterm infants after supplementation of a prebiotic mixture in the neonatal period: a follow-up study</article-title><source>Neuropediatrics</source><year>2014</year><volume>45</volume><fpage>22</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">23888466</pub-id></mixed-citation></ref><ref id="CR18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van den Berg</surname><given-names>JP</given-names></name><name><surname>Westerbeek</surname><given-names>EA</given-names></name><name><surname>Broring-Starre</surname><given-names>T</given-names></name><name><surname>Garssen</surname><given-names>J</given-names></name><name><surname>van Elburg</surname><given-names>RM</given-names></name></person-group><article-title xml:lang="en">Neurodevelopment of preterm infants at 24 months after neonatal supplementation of a prebiotic mix: a randomized trial</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2016</year><volume>63</volume><fpage>270</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">26859091</pub-id></mixed-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dilli</surname><given-names>D</given-names></name><name><surname>Aydin</surname><given-names>B</given-names></name><name><surname>Fettah</surname><given-names>ND</given-names></name><name><surname>Ozyazici</surname><given-names>E</given-names></name><name><surname>Beken</surname><given-names>S</given-names></name><name><surname>Zenciroglu</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">The propre-save study: effects of probiotics and prebiotics alone or combined on necrotizing enterocolitis in very low birth weight infants</article-title><source>J Pediatr</source><year>2015</year><volume>166</volume><fpage>545</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">25596096</pub-id></mixed-citation></ref><ref id="CR20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kapiki</surname><given-names>A</given-names></name><name><surname>Costalos</surname><given-names>C</given-names></name><name><surname>Oikonomidou</surname><given-names>C</given-names></name><name><surname>Triantafyllidou</surname><given-names>A</given-names></name><name><surname>Loukatou</surname><given-names>E</given-names></name><name><surname>Pertrohilou</surname><given-names>V</given-names></name></person-group><article-title xml:lang="en">The effect of a fructo-oligosaccharide supplemented formula on gut flora of preterm infants</article-title><source>Early Hum Dev</source><year>2007</year><volume>83</volume><fpage>335</fpage><lpage>9</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2sXkt1arurs%3D</pub-id><pub-id pub-id-type="pmid">16978805</pub-id></mixed-citation></ref><ref id="CR21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dasopoulou</surname><given-names>M</given-names></name><name><surname>Briana</surname><given-names>DD</given-names></name><name><surname>Boutsikou</surname><given-names>T</given-names></name><name><surname>Karakasidou</surname><given-names>E</given-names></name><name><surname>Roma</surname><given-names>E</given-names></name><name><surname>Costalos</surname><given-names>C</given-names></name><etal/></person-group><article-title xml:lang="en">Motilin and gastrin secretion and lipid profile in preterm neonates following prebiotics supplementation: a double-blind randomized controlled study</article-title><source>JPEN J Parenter Enter Nutr</source><year>2015</year><volume>39</volume><fpage>359</fpage><lpage>68</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2MXktl2ls7g%3D</pub-id></mixed-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luoto</surname><given-names>R</given-names></name><name><surname>Ruuskanen</surname><given-names>O</given-names></name><name><surname>Waris</surname><given-names>M</given-names></name><name><surname>Kalliomaki</surname><given-names>M</given-names></name><name><surname>Salminen</surname><given-names>S</given-names></name><name><surname>Isolauri</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">Prebiotic and probiotic supplementation prevents rhinovirus infections in preterm infants: a randomized, placebo-controlled trial</article-title><source>J Allergy Clin Immunol</source><year>2014</year><volume>133</volume><fpage>405</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">24131826</pub-id></mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Campeotto</surname><given-names>F</given-names></name><name><surname>Suau</surname><given-names>A</given-names></name><name><surname>Kapel</surname><given-names>N</given-names></name><name><surname>Magne</surname><given-names>F</given-names></name><name><surname>Viallon</surname><given-names>V</given-names></name><name><surname>Ferraris</surname><given-names>L</given-names></name><etal/></person-group><article-title xml:lang="en">A fermented formula in pre-term infants: clinical tolerance, gut microbiota, down-regulation of faecal calprotectin and up-regulation of faecal secretory IgA</article-title><source>Br J Nutr</source><year>2011</year><volume>105</volume><fpage>1843</fpage><lpage>51</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3MXmvFGjtbg%3D</pub-id><pub-id pub-id-type="pmid">21426607</pub-id></mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riskin</surname><given-names>A</given-names></name><name><surname>Hochwald</surname><given-names>O</given-names></name><name><surname>Bader</surname><given-names>D</given-names></name><name><surname>Srugo</surname><given-names>I</given-names></name><name><surname>Naftali</surname><given-names>G</given-names></name><name><surname>Kugelman</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">The effects of lactulose supplementation to enteral feedings in premature infants: a pilot study</article-title><source>J Pediatr</source><year>2010</year><volume>156</volume><fpage>209</fpage><lpage>14</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3cXpslCkug%3D%3D</pub-id><pub-id pub-id-type="pmid">19879595</pub-id></mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modi</surname><given-names>N</given-names></name><name><surname>Uthaya</surname><given-names>S</given-names></name><name><surname>Fell</surname><given-names>J</given-names></name><name><surname>Kulinskaya</surname><given-names>E</given-names></name></person-group><article-title xml:lang="en">A randomized, double-blind, controlled trial of the effect of prebiotic oligosaccharides on enteral tolerance in preterm infants (ISRCTN77444690)</article-title><source>Pediatr Res</source><year>2010</year><volume>68</volume><fpage>440</fpage><lpage>5</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC3cXht1yqtr3O</pub-id><pub-id pub-id-type="pmid">20639792</pub-id></mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mihatsch</surname><given-names>WA</given-names></name><name><surname>Hoegel</surname><given-names>J</given-names></name><name><surname>Pohlandt</surname><given-names>F</given-names></name></person-group><article-title xml:lang="en">Prebiotic oligosaccharides reduce stool viscosity and accelerate gastrointestinal transport in preterm infants</article-title><source>Acta Paediatr</source><year>2006</year><volume>95</volume><fpage>843</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16801182</pub-id></mixed-citation></ref><ref id="CR27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>G</given-names></name><name><surname>Fanaro</surname><given-names>S</given-names></name><name><surname>Jelinek</surname><given-names>J</given-names></name><name><surname>Stahl</surname><given-names>B</given-names></name><name><surname>Marini</surname><given-names>A</given-names></name></person-group><article-title xml:lang="en">Prebiotic concept for infant nutrition</article-title><source>Acta Paediatr Suppl</source><year>2003</year><volume>91</volume><fpage>64</fpage><lpage>7</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BD3sritV2msw%3D%3D</pub-id><pub-id pub-id-type="pmid">14599044</pub-id></mixed-citation></ref><ref id="CR28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Henry</surname><given-names>MC</given-names></name><name><surname>Moss</surname><given-names>RL</given-names></name></person-group><article-title xml:lang="en">Neonatal necrotizing enterocolitis</article-title><source>Semin Pediatr Surg</source><year>2008</year><volume>17</volume><fpage>98</fpage><lpage>109</lpage><pub-id pub-id-type="pmid">18395659</pub-id></mixed-citation></ref><ref id="CR29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Srinivasjois</surname><given-names>R</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Patole</surname><given-names>S</given-names></name></person-group><article-title xml:lang="en">Prebiotic supplementation in preterm neonates: updated systematic review and meta-analysis of randomised controlled trials</article-title><source>Clin Nutr</source><year>2013</year><volume>32</volume><fpage>958</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">23786897</pub-id></mixed-citation></ref><ref id="CR30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lohner</surname><given-names>S</given-names></name><name><surname>Kullenberg</surname><given-names>D</given-names></name><name><surname>Antes</surname><given-names>G</given-names></name><name><surname>Decsi</surname><given-names>T</given-names></name><name><surname>Meerpohl</surname><given-names>JJ</given-names></name></person-group><article-title xml:lang="en">Prebiotics in healthy infants and children for prevention of acute infectious diseases: a systematic review and meta-analysis</article-title><source>Nutr Rev</source><year>2014</year><volume>72</volume><fpage>523</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">24903007</pub-id></mixed-citation></ref><ref id="CR31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tulumoglu</surname><given-names>S</given-names></name><name><surname>Erdem</surname><given-names>B</given-names></name><name><surname>Simsek</surname><given-names>O</given-names></name></person-group><article-title xml:lang="en">The effects of inulin and fructo-oligosaccharide on the probiotic properties of Lactobacillus spp. isolated from human milk</article-title><source>Z Naturforsch C</source><year>2018</year><volume>73</volume><fpage>367</fpage><lpage>73</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXhslaitbfM</pub-id><pub-id pub-id-type="pmid">29787377</pub-id></mixed-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vieira</surname><given-names>ADS</given-names></name><name><surname>Bedani</surname><given-names>R</given-names></name><name><surname>Albuquerque</surname><given-names>MAC</given-names></name><name><surname>Biscola</surname><given-names>V</given-names></name><name><surname>Saad</surname><given-names>SMI</given-names></name></person-group><article-title xml:lang="en">The impact of fruit and soybean by-products and amaranth on the growth of probiotic and starter microorganisms</article-title><source>Food Res Int</source><year>2017</year><volume>97</volume><fpage>356</fpage><lpage>63</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXntVart7Y%3D</pub-id><pub-id pub-id-type="pmid">28578060</pub-id></mixed-citation></ref><ref id="CR33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di</surname><given-names>R</given-names></name><name><surname>Vakkalanka</surname><given-names>MS</given-names></name><name><surname>Onumpai</surname><given-names>C</given-names></name><name><surname>Chau</surname><given-names>HK</given-names></name><name><surname>White</surname><given-names>A</given-names></name><name><surname>Rastall</surname><given-names>RA</given-names></name><etal/></person-group><article-title xml:lang="en">Pectic oligosaccharide structure–function relationships: prebiotics, inhibitors of <italic>Escherichia coli</italic> O157:H7 adhesion and reduction of Shiga toxin cytotoxicity in HT29 cells</article-title><source>Food Chem</source><year>2017</year><volume>227</volume><fpage>245</fpage><lpage>54</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC2sXhslSltLs%3D</pub-id><pub-id pub-id-type="pmid">28274429</pub-id></mixed-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Underwood</surname><given-names>MA</given-names></name><name><surname>Sohn</surname><given-names>K</given-names></name></person-group><article-title xml:lang="en">The microbiota of the extremely preterm infant</article-title><source>Clin Perinatol</source><year>2017</year><volume>44</volume><fpage>407</fpage><lpage>27</lpage><pub-id pub-id-type="pmid">28477669</pub-id><pub-id pub-id-type="pmcid">6361543</pub-id></mixed-citation></ref><ref id="CR35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>ZH</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Li</surname><given-names>HD</given-names></name><name><surname>Zhu</surname><given-names>DP</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Hou</surname><given-names>T</given-names></name><etal/></person-group><article-title xml:lang="en">Prenatal and postnatal antibiotic exposure influences the gut microbiota of preterm infants in neonatal intensive care units</article-title><source>Ann Clin Microbiol Antimicrob</source><year>2018</year><volume>17</volume><fpage>9</fpage><pub-id pub-id-type="pmid">29554907</pub-id><pub-id pub-id-type="pmcid">5858143</pub-id></mixed-citation></ref><ref id="CR36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zwittink</surname><given-names>RD</given-names></name><name><surname>Renes</surname><given-names>IB</given-names></name><name><surname>van Lingen</surname><given-names>RA</given-names></name><name><surname>van Zoeren-Grobben</surname><given-names>D</given-names></name><name><surname>Konstanti</surname><given-names>P</given-names></name><name><surname>Norbruis</surname><given-names>OF</given-names></name><etal/></person-group><article-title xml:lang="en">Association between duration of intravenous antibiotic administration and early-life microbiota development in late-preterm infants</article-title><source>Eur J Clin Microbiol Infect Dis</source><year>2018</year><volume>37</volume><fpage>475</fpage><lpage>83</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXhslCgsrk%3D</pub-id><pub-id pub-id-type="pmid">29368074</pub-id><pub-id pub-id-type="pmcid">5816780</pub-id></mixed-citation></ref><ref id="CR37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Marwah</surname><given-names>G</given-names></name><name><surname>Westgarth</surname><given-names>M</given-names></name><name><surname>Buys</surname><given-names>N</given-names></name><name><surname>Ellwood</surname><given-names>D</given-names></name><name><surname>Gray</surname><given-names>PH</given-names></name></person-group><article-title xml:lang="en">Effects of probiotics on necrotizing enterocolitis, sepsis, intraventricular hemorrhage, mortality, length of hospital stay, and weight gain in very preterm infants: a meta-analysis</article-title><source>Adv Nutr</source><year>2017</year><volume>8</volume><fpage>749</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">28916575</pub-id><pub-id pub-id-type="pmcid">5593111</pub-id></mixed-citation></ref><ref id="CR38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Underwood</surname><given-names>MA</given-names></name><name><surname>Salzman</surname><given-names>NH</given-names></name><name><surname>Bennett</surname><given-names>SH</given-names></name><name><surname>Barman</surname><given-names>M</given-names></name><name><surname>Mills</surname><given-names>DA</given-names></name><name><surname>Marcobal</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">A randomized placebo-controlled comparison of 2 prebiotic/probiotic combinations in preterm infants: impact on weight gain, intestinal microbiota, and fecal short-chain fatty acids</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2009</year><volume>48</volume><fpage>216</fpage><lpage>25</lpage><pub-id pub-id-type="pmid">19179885</pub-id><pub-id pub-id-type="pmcid">2743418</pub-id></mixed-citation></ref><ref id="CR39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nandhini</surname><given-names>LP</given-names></name><name><surname>Biswal</surname><given-names>N</given-names></name><name><surname>Adhisivam</surname><given-names>B</given-names></name><name><surname>Mandal</surname><given-names>J</given-names></name><name><surname>Bhat</surname><given-names>BV</given-names></name><name><surname>Mathai</surname><given-names>B</given-names></name></person-group><article-title xml:lang="en">Synbiotics for decreasing incidence of necrotizing enterocolitis among preterm neonates—a randomized controlled trial</article-title><source>J Matern Fetal Neonatal Med</source><year>2016</year><volume>29</volume><fpage>821</fpage><lpage>5</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BC2MnisVejsA%3D%3D</pub-id><pub-id pub-id-type="pmid">25754214</pub-id></mixed-citation></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guney-Varal</surname><given-names>I</given-names></name><name><surname>Koksal</surname><given-names>N</given-names></name><name><surname>Ozkan</surname><given-names>H</given-names></name><name><surname>Bagci</surname><given-names>O</given-names></name><name><surname>Dogan</surname><given-names>P</given-names></name></person-group><article-title xml:lang="en">The effect of early administration of combined multi-strain and multi-species probiotics on gastrointestinal morbidities and mortality in preterm infants: a randomized controlled trial in a tertiary care unit</article-title><source>Turk J Pediatr</source><year>2017</year><volume>59</volume><fpage>13</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">29168358</pub-id></mixed-citation></ref><ref id="CR41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grady</surname><given-names>NG</given-names></name><name><surname>Petrof</surname><given-names>EO</given-names></name><name><surname>Claud</surname><given-names>EC</given-names></name></person-group><article-title xml:lang="en">Microbial therapeutic interventions</article-title><source>Semin Fetal Neonatal Med</source><year>2016</year><volume>21</volume><fpage>418</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">27133778</pub-id><pub-id pub-id-type="pmcid">5079850</pub-id></mixed-citation></ref><ref id="CR42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stinson</surname><given-names>LF</given-names></name><name><surname>Payne</surname><given-names>MS</given-names></name><name><surname>Keelan</surname><given-names>JA</given-names></name></person-group><article-title xml:lang="en">Planting the seed: origins, composition, and postnatal health significance of the fetal gastrointestinal microbiota</article-title><source>Crit Rev Microbiol</source><year>2017</year><volume>43</volume><fpage>352</fpage><lpage>69</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC28XitV2kurnJ</pub-id><pub-id pub-id-type="pmid">27931152</pub-id></mixed-citation></ref><ref id="CR43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watkins</surname><given-names>C</given-names></name><name><surname>Stanton</surname><given-names>C</given-names></name><name><surname>Ryan</surname><given-names>CA</given-names></name><name><surname>Ross</surname><given-names>RP</given-names></name></person-group><article-title xml:lang="en">Microbial therapeutics designed for infant health</article-title><source>Front Nutr</source><year>2017</year><volume>4</volume><fpage>48</fpage><pub-id pub-id-type="pmid">29124056</pub-id><pub-id pub-id-type="pmcid">5662644</pub-id></mixed-citation></ref><ref id="CR44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boehm</surname><given-names>G</given-names></name><name><surname>Moro</surname><given-names>G</given-names></name></person-group><article-title xml:lang="en">Structural and functional aspects of prebiotics used in infant nutrition</article-title><source>J Nutr</source><year>2008</year><volume>138</volume><fpage>1818S</fpage><lpage>28S</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD1cXhtVyksbzO</pub-id><pub-id pub-id-type="pmid">18716193</pub-id></mixed-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agostoni</surname><given-names>C</given-names></name><name><surname>Buonocore</surname><given-names>G</given-names></name><name><surname>Carnielli</surname><given-names>VP</given-names></name><name><surname>De Curtis</surname><given-names>M</given-names></name><name><surname>Darmaun</surname><given-names>D</given-names></name><name><surname>Decsi</surname><given-names>T</given-names></name><etal/></person-group><article-title xml:lang="en">Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2010</year><volume>50</volume><fpage>85</fpage><lpage>91</lpage><pub-id pub-id-type="coi">1:STN:280:DC%2BD1MfkvVehtw%3D%3D</pub-id><pub-id pub-id-type="pmid">19881390</pub-id></mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ballard</surname><given-names>O</given-names></name><name><surname>Morrow</surname><given-names>AL</given-names></name></person-group><article-title xml:lang="en">Human milk composition: nutrients and bioactive factors</article-title><source>Pediatr Clin North Am</source><year>2013</year><volume>60</volume><fpage>49</fpage><lpage>74</lpage><pub-id pub-id-type="pmid">23178060</pub-id><pub-id pub-id-type="pmcid">3586783</pub-id></mixed-citation></ref><ref id="CR47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>DA</given-names></name><name><surname>Pinto</surname><given-names>F</given-names></name><name><surname>Ovalle</surname><given-names>A</given-names></name><name><surname>Thomson</surname><given-names>P</given-names></name><name><surname>Garrido</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Prebiotics mediate microbial interactions in a consortium of the infant gut microbiome</article-title><source>Int J Mol Sci</source><year>2017</year><volume>18</volume><fpage>E2095</fpage><pub-id pub-id-type="pmid">28976925</pub-id></mixed-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>James</surname><given-names>K</given-names></name><name><surname>Motherway</surname><given-names>MO</given-names></name><name><surname>Penno</surname><given-names>C</given-names></name><name><surname>O’Brien</surname><given-names>RL</given-names></name><name><surname>van Sinderen</surname><given-names>D</given-names></name></person-group><article-title xml:lang="en">Bifidobacterium breve UCC2003 employs multiple transcriptional regulators to control metabolism of particular human milk oligosaccharides</article-title><source>Appl Environ Microbiol</source><year>2018</year><volume>84</volume><fpage>e02774</fpage><lpage>17</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BC1cXhslGks7fE</pub-id><pub-id pub-id-type="pmid">29500268</pub-id><pub-id pub-id-type="pmcid">5930313</pub-id></mixed-citation></ref><ref id="CR49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>CJ</given-names></name><name><surname>Embleton</surname><given-names>ND</given-names></name><name><surname>Marrs</surname><given-names>ECL</given-names></name><name><surname>Smith</surname><given-names>DP</given-names></name><name><surname>Fofanova</surname><given-names>T</given-names></name><name><surname>Nelson</surname><given-names>A</given-names></name><etal/></person-group><article-title xml:lang="en">Longitudinal development of the gut microbiome and metabolome in preterm neonates with late onset sepsis and healthy controls</article-title><source>Microbiome</source><year>2017</year><volume>5</volume><pub-id pub-id-type="pmid">28701177</pub-id><pub-id pub-id-type="pmcid">5508794</pub-id></mixed-citation></ref><ref id="CR50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vos</surname><given-names>AP</given-names></name><name><surname>van Esch</surname><given-names>BC</given-names></name><name><surname>Stahl</surname><given-names>B</given-names></name><name><surname>M’Rabet</surname><given-names>L</given-names></name><name><surname>Folkerts</surname><given-names>G</given-names></name><name><surname>Nijkamp</surname><given-names>FP</given-names></name><etal/></person-group><article-title xml:lang="en">Dietary supplementation with specific oligosaccharide mixtures decreases parameters of allergic asthma in mice</article-title><source>Int Immunopharmacol</source><year>2007</year><volume>7</volume><fpage>1582</fpage><lpage>7</lpage><pub-id pub-id-type="coi">1:CAS:528:DC%2BD2sXhtFCjt7bK</pub-id><pub-id pub-id-type="pmid">17920536</pub-id></mixed-citation></ref></ref-list></ref-list><app-group><app id="App1"><sec id="Sec19"><title>Supplementary information</title><p id="Par39"><supplementary-material content-type="local-data" id="MOESM1" xlink:title="Supplementary information"><media xlink:href="MediaObjects/41430_2018_377_MOESM1_ESM.doc" mimetype="application" mime-subtype="msword"><caption xml:lang="en"><p>Checklist</p></caption></media></supplementary-material></p></sec></app></app-group><notes notes-type="ESMHint"><title>Supplementary information</title><p>The online version of this article (<ext-link xlink:href="https://doi.org/10.1038/s41430-018-0377-6" ext-link-type="doi">https://doi.org/10.1038/s41430-018-0377-6</ext-link>) contains supplementary material, which is available to authorized users.</p></notes></back></article></records><facets><facet name="subject"><facet-value count="1">Clinical Nutrition</facet-value><facet-value count="1">Epidemiology</facet-value><facet-value count="1">Internal Medicine</facet-value><facet-value count="1">Medicine &amp; Public Health</facet-value><facet-value count="1">Medicine/Public Health, general</facet-value><facet-value count="1">Metabolic Diseases</facet-value><facet-value count="1">Public Health</facet-value></facet><facet name="keyword"/><facet name="pub"><facet-value count="1">European Journal of Clinical Nutrition</facet-value></facet><facet name="year"><facet-value count="1">2019</facet-value></facet><facet name="country"><facet-value count="1">Australia</facet-value><facet-value count="1">China</facet-value></facet><facet name="type"><facet-value count="1">Journal</facet-value></facet></facets></response>
